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“When the Lord created the world and people to live in it -- an enterprise which, according to 
modern science, took a very long time -- I could well imagine that He reasoned with Himself 
as follows: "If I make everything predictable, these human beings, whom I have endowed 
with pretty good brains, will undoubtedly learn to predict everything, and they will thereupon 
have no motive to do anything at all, because they will recognize that the future is totally 
determined and cannot be influenced by any human action. On the other hand, if I make 
everything unpredictable: they will gradually discover that there is no rational basis for any 
decision whatsoever and, as in the first case, they will thereupon have no motive to do 
anything at all. Neither scheme would make sense. I must therefore create a mixture of the 
two. Let some things be predictable and let others be unpredictable. They will then, amongst 
many other things, have the very important task of finding out which is which." 
 

























Table of contents   
   
Abstract   
   English 12  
   Spanish 13  
   
Chapter 1 15  
   Introduction   
   
Chapter 2 23  
   Aims and hypotheses   
   
Chapter 3 27  
Study 1. Urine ethyl glucuronide unraveling the reality of abstinence monitoring in a       
routine outpatient setting: a cross-sectional comparison with ethanol, self-report and 
clinical judgment.  
 
   
Chapter 4 39  
Study 2. One year clinical correlates of EtG positive urine screening in alcohol 
dependent patients: a survival analysis.  
  
   
   
Chapter 5 51  
Study 3.Patients’ knowledge and attitudes towards regular alcohol urine screening: a 
survey study.  
  
   
Chapter 6 63  
 General discussion   
   
Chapter 7 77  
   Conclusions   
   
Resumen en castellano 79  
List of abbreviations   91  
References 93  
Acknowledgements 103  




































































The development of an alcohol biomarker is a long process where different stages take 
place over time. From discovery to full clinical use and implementation, each accomplished 
stage increases the confidence in and the relevance of such biomarkers. In recent years, 
new biomarkers have been discovered, with outstanding improvements in the sensibility and 
specificity for the detection of recent drinking. However, the clinical, therapeutic and 
economical consequences of such biochemical improvements remain to be determined. 
With the present thesis we expect to investigate the clinical implications of such new 
biomarkers, with a special focus on urine ethyl glucuronide (EtG), in order to fully establish 
its contribution to the field of alcohol use disorders. It comprises three articles: the first 
(Study 1) compares the screening performance of ethyl glucuronide versus ethanol, clinical 
judgment and self report, under routine, real circumstances in alcohol dependent 
outpatients. The second one (Study 2) investigates the differential, one-year clinical 
evolution of patients screening positive and negative in Study 1, taking into account both 
clinical and economic consequences. Finally, Study 3 evaluates patients’ knowledge and 
attitudes towards regular alcohol urine screening.  
 
Methods 
Study 1 consisted of a cross-sectional comparison aiming at clinically validating EtG under 
real, routinely clinical conditions. For that purpose, 613 consecutive urinary samples, 
provided by 188 outpatients with alcohol dependence were analyzed for ethanol and EtG. 
Study 2 retrospectively assessed the clinical evolution of patients participating in Study 1. A 
survival analysis was conducted in order to compare the rate of relapse between EtG 
positive and negative patients. Regression models were performed to compare the mean 
number of days hospitalized between groups, the risk of being lost to follow-up and 
treatment expenses. In Study 3 a cross-sectional survey among alcohol dependent 
outpatients was conducted. In consonance with the principles of patient centered care, it 
aimed at investigating patients’ attitudes and beliefs towards regular alcohol urine screening. 
For attitudes’ assessment, we adapted the Drug Attitude Inventory (DAI-10) to the field of 
alcohol urine screening. Internal consistency, test-retest reliability and concurrent validity 
were evaluated for the adapted questionnaire.  
 
Results 
Study 1 showed an overriding superiority of EtG over ethanol, clinical judgment and self 
report, detecting a significant greater number of positive samples in routine, real 
circumstances. Study 2 revealed a clearly different clinical evolution between EtG positive 
and negative patients during the following 12 months, with EtG positive patients being at 
greater risk of relapse, hospitalization and incurring in more treatment expenses. Study 3 
suggested that regular alcohol screening is highly valued by alcohol outpatients. It also 
showed that besides relapse prevention, other functions related to therapeutic alliance 
building, social desirability and impression management play a key role as well.   
 
Conclusions 
Regular alcohol urine screening with ethyl glucuronide seems to have an impact on the 
clinical management of alcohol dependent outpatients, offering a better detection of recent 






El desarrollo de biomarcadores para el consumo de alcohol es un proceso largo y laborioso, 
donde múltiples etapas se suceden en el tiempo. Desde su descubrimiento en el laboratorio 
hasta su total implementación clínica, cada etapa superada incrementa la confianza y la 
relevancia de dicho marcador. En los últimos años se han descubierto marcadores que 
cuentan con una notable sensibilidad y especificidad en cuanto a la detección de consumo 
reciente se refiere. Sin embargo, las implicaciones clínicas, terapéuticas y económicas de 
dichos marcadores todavía no han sido esclarecidas con total claridad. Con la presente 
tesis se pretende investigar las implicaciones clínicas de dichos nuevos marcadores, 
específicamente del etilglucurónido (EtG), con el objetivo de determinar su verdadera 
aportación al campo de los trastornos por uso de alcohol. Esta tesis está compuesta de tres 
artículos. El primero (Estudio 1) compara el rendimiento en el cribado de consumo de 
alcohol del etilglucurónido frente al etanol, el juicio clínico y el autoinforme, bajo condiciones 
rutinarias y reales en pacientes dependientes del alcohol ambulatorios. El segundo artículo 
(Estudio 2) investiga la evolución clínica diferencial entre los pacientes que obtuvieron un 
resultado positivo y uno negativo en el Estudio 1, durante los siguientes 12 meses. 
Finalmente, el tercer artículo (Estudio 3) evalúa los conocimientos y la actitud que los 
pacientes presentan ante el cribado rutinario de alcohol.  
 
Métodos 
El Estudio 1 consistió en una comparación transversal cuya finalidad fue la de evaluar el uso 
de EtG bajo condiciones clínicas rutinarias de elevada validez externa. Para ello 613 
muestras de orina consecutivas, proporcionadas por 188 pacientes ambulatorios con 
dependencia al alcohol, fueron analizadas para etanol y etilglucurónido. El Estudio 2 evaluó 
retrospectivamente la evolución clínica de los participantes del Estudio 1. Se llevó a cabo un 
análisis de supervivencia con el fin de comparar la tasa de recaída entre pacientes con un 
resultado positivo y negativo a etilglucurónido. Se realizaron análisis de regresión para 
comparar entre grupos el número medio de días hospitalizados, el riesgo de abandonar 
tratamiento y los costes medios del tratamiento.  En el Estudio 3, en consonancia con los 
principios de la medicina centrada en el paciente, se realizó una encuesta a pacientes con 
dependencia del alcohol ambulatorios con la finalidad de evaluar sus actitudes, creencias y 
conocimientos en relación al cribado rutinario de alcohol en orina. Para la evaluación de sus 
actitudes se adaptó la escala Drug Attitude Inventory (DAI-10), analizándose su consistencia 
interna, su fiabilidad test-retest y su validez concurrente.  
 
Resultados 
El Estudio 1 mostró una clara superioridad del EtG sobre el etanol, el juicio clínico y el 
autoinforme, detectando un mayor número de positivos en condiciones reales de elevada 
validez externa. El Estudio 2 demostró una clara y diferente evolución clínica entre los 
pacientes que fueron EtG positivo y EtG negativo durante los siguientes 12 meses, 
presentando los pacientes EtG positivo un mayor riesgo de recaída, de hospitalización así 
como mayores costes de tratamiento. El Estudio 3 sugirió que el cribado rutinario de alcohol 
en orina es percibido por los pacientes dependientes al alcohol como un elemento valioso 
de su tratamiento. Se observó también que, además de cumplir una función de prevención 
de recaídas, otras funciones relacionadas con el vínculo terapéutico, la conveniencia social 





El cribado rutinario de alcohol mediante EtG parece tener un impacto en el manejo de los 
pacientes dependientes al alcohol ambulatorios, ofreciendo una mejor detección del 
































































































The burden and size of the problem 
 
The global burden of disease from alcohol use is second only to tobacco and hypertension 
(1). Alcohol is responsible for 5,9% of mortality worldwide (2), meaning that 2,5 million people die 
each year because of alcohol (3). In the U.S. it represents the third leading cause of preventable 
death (4), while Europe, with 15 million people affected by alcohol use disorders (5), has the highest 
alcohol-attributable deaths and disability-adjusted life years (DALYs) in the world (13.3% of deaths 
and 12.8% of DALYs are attributable to alcohol) (2). On top of that, the well-known treatment gap of 
alcohol use disorders (6–8), where approximately only 1 in 10 patients receive treatment, increases 
the magnitude of this burden. But not only affected individuals, treated or not, must assume alcohol 
consequences. Societies as a whole do also suffer its consequences. In fact, a  recent systematic 
review concluded that most of the costs alcohol produces are born by non-affected individuals, i.e., 
society as a whole (9). Therefore, the size and the consequences of the problem clearly suggest that 
alcohol should be a top priority from a public health perspective.  
 
Alcohol use disorders 
 
Most of the consequences and burden of disease produced by alcohol stem from people 
affected by the severest form of alcohol use disorder (AUD) (10), formerly called alcohol dependence 
under DSM-IV (11). A solid body of evidence demonstrates that severe AUD (or alcohol dependence) 
is a chronic condition, usually with a relapse-remitting course (12–14). Studies also suggest it is a 
multifactorial disease, where complex genetic-environmental interactions occur. Both twin studies (15) 
and genome wide association studies (GWAS) (16) show that genetic influences exert a moderate to 
high etiological influence in its development (17).  
The consequences suffered by affected individuals are several and diverse. From organic to 
psychiatric symptoms, manifestations of alcohol use may appear on any organ system of the body 
(18,19). Common behavioral, psychiatric, social, or medical manifestations of alcohol dependence 
include trauma or injury, anxiety, depression, suicidality, hypertension, gastrointestinal symptoms, 
cardiac symptoms, central or peripheral neurologic symptoms, electrolyte disturbances, sleep 
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disturbances, increased liver enzymes, macrocytosis and social or legal problems. Importantly, 
alcohol remains the most common cause of liver cirrhosis in Western World (20). 
In consonance with the prevalence, magnitude and consequences of alcohol use, a majority 
of guidelines advocate for the universal implementation of screening for alcohol use disorders in 
primary care (21,22). Systematic screening should allow primary care physicians to identify and offer 
treatment to mild and moderate forms of AUD, while at the same time identify more severe forms and 
refer them to specialized treatment. Screening of AUD in primary care is usually conducted with short 
and easy to use questionnaires, such as the AUDIT-C. Ancillary tests, such as blood examination, can 
play also a part in identifying affected individuals.   
 
Regarding the treatment of alcohol use disorders, It is widely agreed that the basis of 
treatment remains psychosocial in essence (23). However, it is probable that the combination of 
psychosocial and pharmacological treatments might offer the most efficacious treatment for affected 
individuals (24).  
While a full review of the treatment of AUD is beyond the scope of this thesis, it can be said 
that a variety of options with solid evidence exist for both psychosocial and pharmacological 
treatments. In the area of psychosocial interventions, motivational interviewing, cognitive behavioral 
therapy, peer support groups, family therapy, contingency management and social behavioral network 
therapy have proven its efficacy (25–32). From the pharmacological point of view, different treatments 
have proven efficacy, such as naltrexone, acamprosate, disulfiram, baclofen and topiramate (33–37).  
 
Treatment goals in alcohol use disorders 
 
A relevant question in the treatment of alcohol use disorders, such as in any other disease, 
are treatment goals. Broadly speaking, restoration of physical, mental and social well-being could be 
considered the main treatment aims. This broad definition encompasses the idea that outcome 
expectancies in alcohol dependence treatment should not be limited to the amount of alcohol ingested 
(38). However, it is almost self-evident that, in fact, the amount of drinking is of paramount importance 
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when evaluating patients’ clinical evolution and response to treatment, and that the amount of alcohol 
has a direct causal relationship with many of the problems that patients have on multiple life areas 
(39). Putting it simple, when it comes to specific drinking outcomes, usually two options arise: 
reduced/controlled drinking or abstinence. 
Despite harm reduction strategies being frequently considered and used in addiction settings, 
and despite some controversies in the field (40–42), abstinence has been the prevailing therapeutic 
goal in most of the existing settings, being considered  the safest and most efficient pathway to early 
recovery (43,44). This fact is not surprising, since addiction has usually been conceptualized as 
impaired control over a substance. Moreover, longitudinal studies have called into question the 
adequacy of controlled-drinking paradigms as long-term strategies for moderate and severe alcohol 
dependent patients (45,46).  
Therefore, it becomes clear that being able to properly monitor abstinence is of key 
importance in the field of alcohol use disorders.    
 
Monitoring abstinence in alcohol use disorders 
 
Professionals dispose mainly of two types of tools to undertake this salient job. First, patients’ 
self-reports. For many years, they were, besides clinician's’ judgment, the only available instrument. 
Despite all the advances in biological markers, they remain as one key component of routine clinical 
care in many settings (47). Nonetheless, they suffer from some important pitfalls, especially regarding 
their sensitivity in detecting alcohol consumption. Some of the reasons underlying this shortcoming 
might be cognitive deficits, fear of putting treatment in danger, fear of legal consequences or social 
desirability (48). Some of these might be overcome with alcohol biomarkers. They should not be 
considered as substitutes of self-reports, but rather a complementary element that might yield 
important contributions in different situations, such as outcome measures in research studies, screens 
for alcohol problems in individuals unable to provide accurate self- reports, or as an instrument to 
increase the accurateness of abstinence monitoring (49).   
Alcohol biomarkers can be obtained from a variety of sources. Blood, breath and urine are the 
most common. While some of them should be considered as markers of heavy use over time, others 
are better suited for abstinence monitoring. For example, traditional markers such as gamma-glutamyl 
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transferase  (GGT) or mean corpuscular volume (MCV) need prolonged ingestion of relatively high 
amounts of alcohol to become elevated (50,51). Even carbohydrate deficient trasnferrin (CDT), which 
certainly improves the specificity of traditional biomarkers, requires at least a few drinks a day for two 
weeks to become elevated (52). Hence, they do not seem feasible candidates for a proper abstinence 
monitoring system, since they would be unable to detect single lapses or short term relapses. 
Moreover, they are measured in blood samples, a fact that limits its usefulness as a routine screening 
method. 
In this sense, urine offers some relevant advantages over blood specimens as screening tests 
in routine clinical practice, especially when patients have to undergo frequent testing. It is indeed 
frequent practice in many abstinence oriented settings, where patients undergo regular urine 
screening to monitor abstinence (53). 
Until recently, urinary ethanol had been the main marker used. Similar to breath alcohol 
testing, its main pitfall is that it only remains positive for a few hours after alcohol ingestion, therefore 
precluding a proper monitoring of abstinence (54). Fortunately, in the field of alcohol biomarkers, 
some recent advances display promising features, that could allow the overcoming of some of the 
previously mentioned shortcomings.  
 
Ethyl glucuronide  
 
The most relevant biomarker and the subject of the present thesis is urine ethyl glucuronide 
(EtG), a non-volatile, water-soluble, stable, direct metabolite of ethanol. Its formation takes place via 
glucuronidation after ethanol ingestion. Although only about 0.5% of all the ethanol ingested 
undergoes this degradation pathway, it remains detectable in urine for up to 72h, depending on the 
amount of ethanol ingested (55). Therefore, it expands the time window for the detection of recent 
alcohol consumption in urine samples. This might offer relevant improvements in clinical practice, in 
as much as covert drinking might be more frequently detected and so earlier addressed, both in a 
feasible and cost-effective manner. While the gold standard for EtG measurement is liquid 
chromatography–tandem mass spectrometry (LC–MS/MS), the appearance of a commercially 
available enzyme immunoassay (EIA) method based on a monoclonal antibody (DRI Ethyl 
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Glucuronide Enzyme Immunoassay, DRI-EtG EIA, Thermo Fisher Scientific Diagnostics, Hemel 
Hempstead, UK) has made the seriated measurement of EtG a feasible and price-affordable reality in 
routine clinical settings.  
It is important to note that other recent alternatives exist besides EtG. However, none of them 
seems nowadays optimal enough for a routine clinical use. For example, transdermal alcohol monitors 
allow for continuous assessment of alcohol concentrations, but cost, stigma and feasibility deterrents 
preclude its wide implementation (56). Phosphatidylethanol is another recent biomarker that has 
shown a relatively good potential to detect recent drinking with a detection window of up to 2 weeks. 
Due to improvements in its measurement, based on LC-MS/MS techniques, its sensitivity has 
increased for the detection of low quantities of drinking. However, it is only measurable in blood 
(57,58). Finally, ethyl sulfate is another biomarker that performs well for recent drinking detection, but 
no commercially available immunoassay exists to date, making its routine implementation more costly 
and difficult (57,59).  
 
Justification of this thesis 
 
Several studies exist up to date focused on urine ethyl glucuronide. While many studies have 
focused on the kinetics of EtG under controlled drinking designs (60–63), the ultimate relevance of 
EtG, as with any other diagnostic tool, is how it performs with real patients in real circumstances. In 
this sense, many studies have tested urinary EtG for the detection of recent drinking, consistently 
reporting a better detection capacity compared to other biomarkers, usually self-reports or breath 
alcohol. However, the majority of these studies have been conducted in artificial conditions or 
experimental settings, or have been embedded in trials aimed at other investigations (61,64–67). 
While experimental designs are essential for internal validity assessment, it has been extensively 
noted in many areas that external validity remains disproportionally neglected (68–70). This fact might 
yield relevant consequences, such as the fact that patients from experimental settings might differ 
significantly from patients in routine settings (71,72), ultimately jeopardizing the feasibility, applicability 
and even the relevance of experimental findings (73). Other concerns regarding previous EtG studies 
are small sample sizes or the use of inpatient populations (74–77). Therefore, we believe that it is 
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important to assess the performance of EtG in “the real world”. This is in fact the aim of Study 1, 
where EtG performance was compared to that of ethanol, self report and clinical judgment under 
routine, clinical circumstances in a cross-sectional design. 
Other relevant concerns remain in the field of routine urine testing for abstinence monitoring 
in alcohol dependent outpatients. Despite the intuition that a higher detection capacity would translate 
into more efficacious and efficient clinical care, there is a paucity of data addressing this question. A 
recent systematic review (78) found little evidence in favor of the clinical utility of conducting urine 
drug screening, outlining that only a few, ill-powered studies have directly addressed this question. 
Taken together, it seems like, despite being such a frequent technique (53) there is a paucity of 
evidence supporting its utility. In fact, no previous research has evaluated the clinical implications of 
an EtG positive screen, in terms of relapse risk, treatment expenses and risk of subsequent 
hospitalization. This question will be addressed in Study 2, where patients participating in Study 1 
were followed during the next 12 months, in order to conduct a survival analysis aimed principally at 
investigating the differential relapse and hospitalization risk between EtG positive and negative 
patients.  
Taking all previous existing research into account, it seems that, so far, conventional urine 
screening for alcohol outpatients, conducted with suboptimal biomarkers, has been far from 
satisfactory in monitoring abstinence. When assessing this fact, some related questions seem to 
emerge: what are the reasons underlying this poor effectiveness? Does urine screening serve other 
functions besides monitoring abstinence, such as offering ongoing support? What do patients know 
about urine screening, and what are their attitudes towards it? Study 3 tries to unravel some of the 
answers to these questions by focusing on patients’ knowledge and attitudes towards regular alcohol 
urine screening. It is important to remember that, in line with the increasing importance of patient-
centered care as a central tenet of high-quality health care delivery (79) also in the field of alcohol 
dependence (80,81), patients always have a unique perspective on any service or intervention they 
receive. Hence, their input becomes an essential component of service evaluation and improvement. 
While there a multiple surveys among professionals regarding urine drug screening (82–86), to the 























































1. To increase the available evidence supporting the utility of routine urine screening for the 
management of alcohol use disorder patients.  
2. To investigate, under routine clinical conditions, the differential sensitivity of urinary ethanol 
and urine ethyl glucuronide for the detection of recent drinking, in alcohol dependent 
outpatients attending an abstinence oriented program. 
3. To investigate whether a positive urine ethyl glucuronide predicts a greater number of 
hospitalizations and health resource consumption during the following 12 months.  
4. To investigate whether a single urine ethyl glucuronide positive screening could predict relapse 
in the following 12 months, and compare the risk of relapse between positive and negative 
ethyl glucuronide patients in the following 12 months.  
5. To assess the reasons why alcohol dependent outpatients attend a routine urine screening 
program.  







1. To investigate the accuracy of self-report using ethyl glucuronide as a gold standard 
2. To investigate the validity of clinical judgment for the detection of recent drinking using ethyl 
glucuronide as a gold standard.   
3. To investigate whether an ethyl glucuronide positive screening increases the risk of treatment 
abandonment.  
4. To investigate patients’ knowledge about different possibilities for alcohol urinary screening, 








1. Given its higher sensibility, and specially its longer detection window, we hypothesize that 
ethyl glucuronide performance in urine screening will result in a greater number of positives 
compared to ethanol in the detection of recent drinking. We also hypothesize that ethyl 
glucuronide will detect more patients with recent drinking than clinical judgment.  
2. Given that relapses are frequently initiated in the form of lapses, a more sensible biomarker, 
such as ethyl glucuronide, could help identify patients in the early phases of relapse, therefore 
we hypothesize that patients with a positive baseline ethyl glucuronide will have a greater 
number of relapses and health resource consumption during the following 12 months, as 
compared to patients with a negative result. 
3. Due to its novelty and its technical aspects, we expect patients to have a low level of 
knowledge regarding EtG as well as other concepts related to urine screening, including the 
detection window of EtG. 
4. Assuming alcohol dependent patients have diverse reasons and expectations towards regular 
urine screening, we hypothesize that patients will show mixed results regarding their attitudes 
towards urine screening. It is expected that some of them will see it as a helpful aid in 
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Based on hypothesis #1, the aim of this study was to investigate, under routine clinical 
conditions, the differential screening performance of urinary ethanol and ethyl glucuronide for the 
detection of recent drinking, in alcohol dependent outpatients attending an abstinence oriented 
program. We further evaluated the differential screening performance of ethyl glucuronide and 
clinician judgment for the detection of recent drinking, and also tried to investigate variables 




We performed a cross sectional study comparing the detection capacity of ethanol and EtG 
in urine samples provided from subjects attending the outpatient service of the Addictive Behaviors 
Unit in a tertiary care Hospital in Barcelona.   
           Urine samples were collected from patients attending the outpatient service of the Addictive 
Behaviors Unit, where routine urine screen is an established procedure for the monitoring of 
abstinence and relapse prevention.  Both patients and their treating professionals were unaware of 
study procedures and results. 
EtG was measured with a commercially available enzyme immunoassay (EIA) method 
based on a new monoclonal antibody (DRI Ethyl Glucuronide Enzyme Immunoassay , DRI-EtG EIA, 
Thermo Fisher Scientific Diagnostics, Hemel Hempstead, UK). The comparison of the DRI-EtG EIA 
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with a reference LC-MS method for 126 urine samples (100 – 50.000 ng/mL) was made with 
Passing-Bablok regression (EIA= -0,104  + 0,960 LC-MS).  Both methods showed an overall good 
and statistically significant agreement r2=0,961 (P<0,0001). 
The DRI-EtG EIA is a semi-quantitative method with a clinical cut off of 500 ng/mL. It also 
offers a low and clinically relevant analytical range (15.3 – 2000 ng/mL). Samples with EtG above 
2000 ng/mL were diluted 1/10 increasing its analytical range until 20000 ng/mL. This method has 
been adapted to the ADVIA 1800 Chemistry System, (Siemens Healthcare Diagnostics, Tarrytown, 
USA) to improve the throughput and the easiness of the analysis. Before analyzing the samples, two 
control levels (375 ng/mL and 625 ng/mL) were processed in order to ensure a correct analysis. 
 Routine sociodemographic as well as disease characteristics were collected from patients’ 
medical chart. The attending nurse, an experienced clinician in the field of addiction, meets every 
patient that undergoes urine screening. The encounter usually takes the form of a brief (usually less 
than 5 minutes), non structured meeting, where patients’ self-report is collected, and in case it is 
necessary, other clinical information is exchanged, sometimes in the form of brief advice, sometimes 
in a more informal manner. It was during these meetings that the nurse also provided her clinical 
judgment regarding the drinking status of the patient, in a qualitative way (patient is totally abstinent: 
yes, no).  
We also collected whether patients were on disulfiram or another aversive medication, 
whether other substances were searched in the urine sample, and if any of the co-screenings 
resulted in a positive result. Weekly frequency of urine testing (less than once weekly, once weekly 
or more than once weekly) was also collected. 
 Sociodemographic characteristics of the sample were described for all subjects providing 
urine samples. Quantitative comparative analyses were performed between the rate of positive 
results of ethanol and EtG. In ethanol negative subjects, comparisons were conducted between 
subjects with positive or negative EtG, followed by regression analysis as a mean to investigate if 
there were any features predicting the positivity of EtG. The detection performance of clinical 
judgment was further assessed using EtG as a gold standard to calculate the area under the 






A total of 188 patients provided 613 consecutive urine samples, in a 14-days period.  
Regarding the total amount of positives, urinary ethanol resulted in 9 positive samples 
belonging to 8 patients. EtG yielded 136 positive samples belonging to 74 patients. Most of EtG 
positive samples (125) were negative for alcohol. It means that 20,4% of the total urine samples 
(125/613) were discordant regarding EtG and ethanol. All urinary alcohol positives resulted in EtG 
positives. 
The percentage of co-screened samples for other substances was 28,1% (172/613). 
Cannabis was the main substance investigated (125/613 urine samples), resulting in a 9,6% of 
positives when calculated for the total sample (59/613).  EtG was positive in 14,6% of the samples of 
patients being on aversive medications and in 26,4% of patients who were not in treatment with 
aversives. The group being screened less than weekly resulted in a 30,8% of positive EtG urine 
samples, those screened once weekly in 16,1% of positives and those screened more than once 
weekly in 23,5% of positive samples. 
In the logistic regression model the following variables were entered: sex, age, duration and 
frequency of urine screening, coscreening to other substances, positive to other substances, clinical 
judgment and being on aversive medication. Of these, only being on aversive medication and clinical 
judgment resulted in significant effects. 
Regarding the diagnostic performance of the nurse, she judged 89,7% (550/613) of the 
samples, belonging to 178 patients, as abstinent. She deemed 7,8% (48/613) of the samples, 
belonging to 26 patients, as not abstinent, and was unsure in 15 samples from 15 patients. When 




EtG performed largely better than ethanol for urine screening in alcohol outpatients, 
detecting an extra 20,4% (125 out of 613) of positives. It means that for each ethanol positive 
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sample, there were approximately 15 EtG positive samples. Although better than ethanol, clinician 
judgment performed also deficiently. Taken together, both the possibility of a more cost-effective 
quantification method and the confirmation of a clearly better performance in routine clinical 
conditions for the screening of alcohol dependent outpatients, suggest that EtG implementation 
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178 patients as belonging to abstinent patients. She was un-
sure in 15 samples from 15 patients. When comparing it 
against EtG as the gold standard, the area under the curve 
was 0.592. Self reports were extremely unreliable in this 
study, with only 5 patients reporting drinking in a total of 6 
urine samples. In the logistic regression model, only aversive 
medications (OR 2.1, 95% CI 1.3–3.3) and clinician judgment 
(OR 2, 95% CI 1.4–2.9) resulted in significant effects.  Conclu-
sions: EtG performed largely better than ethanol for urine 
screening in alcohol outpatients, detecting an extra 20.4% 
(125 out of 613) of positives. It means that for each alcohol-
positive sample, there were 15 EtG-positive samples. Al-
though better than ethanol, clinician judgment was also not 
performed efficiently. If routinely implemented in the 
screening of alcohol outpatients, EtG might bring relevant 
changes that merit further research.  © 2016 S. Karger AG, Basel 
 Introduction 
 The global burden of disease from alcohol is second 
only to tobacco and hypertension  [1] . To prevent and re-
duce health and social problems related to alcohol use, 
biological markers capable of monitoring alcohol con-
sumption with a high sensitivity and specificity are re-
 Key Words 
 Alcohol · Ethyl glucuronide · Abstinence · Recent drinking · 
Monitorization · Relapse prevention 
 Abstract 
 Aims: To test the screening performance of urinary ethyl 
glucuronide (EtG) under routine clinical conditions in a sam-
ple of alcohol-dependent outpatients, comparing it against 
urinary ethanol, self reports and clinical judgment.  Methods: 
A cross-sectional study under routine conditions was con-
ducted in February 2015, where 613 consecutive urinary 
samples, provided by 188 outpatients with alcohol use dis-
orders, were analyzed for ethanol and EtG (cut-off level = 500 
ng/ml). Clinical variables such as the presence of aversive 
medication, comorbidities and clinician judgment were also 
collected. The discrepancy between the number of alcohol 
and EtG positives was recorded. A logistic regression analysis 
including clinical variables was conducted to assess for pre-
dictors of EtG positivity.  Results: Urinary alcohol yielded 9 
positives (1.5% of all urine samples) belonging to 8 patients. 
EtG yielded 136 positives (22% of all urine samples) belong-
ing to 74 patients. Of these, 93.4% (127 of 136) were negative 
for alcohol. All urinary alcohol positives resulted in EtG posi-
tives. The clinician judged 48 samples from 26 patients as 
belonging to not abstinent patients and 550 samples from 
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quired. Traditional markers of alcohol consumption, 
such as gamma glutamyltransferase (GGT), mean cor-
puscular volume (MCV) or carbohydrate deficient trasn-
ferrin (CDT) reflect persistent consumption of higher 
amounts of alcohol (>2 weeks, >1,000 g of ethanol in 
2 weeks). However, in many instances it is of utmost im-
portance to detect even single-drink or short-term con-
sumption events, for example, in abstinence-oriented 
programs, where full relapses might get initiated weeks 
before in the form of ‘lapses’. In such cases, traditional 
markers are usually of low usefulness.
 For many years, in abstinence-oriented settings, urine 
or breath ethanol has been the mainstay of biological test-
ing for alcohol consumption. Nonetheless, some limita-
tions exist regarding its efficacy, mainly with regard to the 
time spectrum of detection, covering only the 6–8 h fol-
lowing alcohol use. Thus, a notable gap exists between the 
8 h after ingestion and the 1–2 weeks needed to see eleva-
tions in CDT, GGT or MCV. Ethyl glucuronide (EtG), a 
non-volatile, water-soluble, stable, direct metabolite of 
ethanol appears to partly fill the gap. Although only about 
0.5% of all the ethanol ingested undergoes this degrada-
tion pathway, it remains detectable in urine for up to 72 
h, depending on the amount of ethanol ingested  [2] . 
Therefore, it expands the time window for the detection 
of recent alcohol consumption in urine samples. This 
might offer relevant improvements in clinical practice; 
especially with covert drinking, which might be more fre-
quently detected and so earlier addressed both in a fea-
sible and cost-effective manner.
 Although some alternatives might exist besides EtG, 
none of them seems, nowadays, optimal enough for rou-
tine clinical use. For example, transdermal alcohol moni-
tors allow for continuous assessment of alcohol concen-
trations, but cost, stigma and feasibility deterrents pre-
clude its wide implementation  [3] . Phosphatidylethanol 
is another recent biomarker that has shown a relatively 
good potential to detect recent drinking with a detection 
window of up to 2 weeks. Due to improvements in its 
measurement, now based on LC-MS/MS techniques, its 
sensitivity has increased for detecting low quantities of 
drinking. However, it is only measurable in blood  [4, 5] . 
Finally, ethyl sulfate is another biomarker that performs 
well for recent drinking detection, but no commercially 
available immunoassay exists to date, making its routine 
implementation more costly and difficult  [4, 6] .
 While many studies have focused on the kinetics of EtG 
under controlled drinking designs  [7–10] , the ultimate 
relevance of EtG, as with any other diagnostic tool, is how 
it performs with real patients in real circumstances. In this 
sense, many studies up to date have tested urinary EtG for 
the detection of recent drinking, consistently reporting a 
better detection capacity compared to other biomarkers, 
usually self-reports or breath alcohol. However, a major-
ity of studies have been conducted in artificial conditions 
or experimental settings, or have been embedded in trials 
aimed at other investigations  [11–15] . While experimen-
tal designs are essential for internal validity assessment, it 
has been extensively noted in many areas that external va-
lidity remains disproportionally neglected  [16–18] . This 
fact might yield relevant consequences, such as the fact 
that patients from experimental settings might differ sig-
nificantly from patients in routine settings  [19, 20] , ulti-
mately jeopardizing the feasibility, applicability and even 
the relevance of experimental findings  [21] . Other con-
cerns regarding previous EtG studies are small sample siz-
es or the use of inpatient populations  [22–25] . Therefore, 
we believe that it is important to assess the performance 
of EtG in ‘the real world’.
 In this study, we compared the detection performance 
of urinary EtG with that of self reports and urinary etha-
nol in a large sample of outpatients with alcohol use dis-
orders. Also, our design gave us the opportunity to incor-
porate clinician judgment as a comparator, which is a rel-
evant element in clinical settings that is often neglected in 
experimental conditions. All in all, we aimed at assessing 
the performance of urinary EtG for the detection of re-
cent drinking under routine conditions, in an actual out-
patient clinical setting, and at evaluating the differences 
that the implementation of EtG might yield, as compared 
to the other screening methods investigated in this study.
 Methods 
 Study Design and Study Subjects 
 We performed a cross-sectional study comparing the detection 
capacity of ethanol and EtG in urine samples obtained from sub-
jects attending the outpatient service of the Addictive Behaviors 
Unit in a tertiary care hospital in Barcelona.
 Procedure 
 Ethics approval was obtained from the local Institutional Re-
view Board. Urine samples were collected from patients attending 
the outpatient service of the Addictive Behaviors Unit, where rou-
tine urine screen is an established procedure for monitoring absti-
nence and relapse prevention. Given that patients are usually re-
quired to provide frequent urine samples for a closer monitoring, 
the number of patients providing the urine samples was expected 
to be less than the total number of urine specimens.
 As part of the clinical routine, the attending nurse stored the 
consecutive urine samples during the timeframe between 8 a.m. 
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laboratory, where they underwent the analysis for ethanol as well 
as the analysis for EtG, using the enzymatic immunoassay kits pro-
vided by Thermo Fisher Scientific.
 EtG Measuring 
 EtG was measured with a commercially available enzyme im-
munoassay (EIA) method based on a new monoclonal antibody 
(DRI-EtG EIA, Thermo Fisher Scientific Diagnostics, Hemel 
Hempstead, UK). The comparison of the DRI-EtG EIA with a ref-
erence LC-MS method for 126 urine samples (100–50,000 ng/ml) 
was made with Passing-Bablok regression (EIA = –0.104 + 0.960 
LC-MS). Both methods showed an overall good and statistically 
significant agreement r 2 = 0.961 (p < 0.0001)  [25] .
 The DRI-EtG EIA is a semi-quantitative method with a clinical 
cut off of 500 ng/ml. It also offers a low and clinically relevant an-
alytical range (15.3–2,000 ng/ml). Samples with EtG above 2,000 
ng/ml were diluted in the ratio 1: 10 increasing its analytical range 
until 20,000 ng/ml. This method has been adapted to the ADVIA 
1800 Chemistry System (Siemens Healthcare Diagnostics, Tarry-
town, USA) to improve the throughput and to conduct the analy-
sis easily. Before analyzing the samples, 2 control levels (375 and 
625 ng/ml) were processed in order to ensure correct analysis.
 Data Collection 
 Routine sociodemographic as well as disease characteristics 
were collected from patients’ medical charts. The attending nurse, 
an experienced clinician in the field of addiction, meets every pa-
tient that undergoes urine screening. The encounter usually takes 
the form of a brief (usually less than 5 min), non-structured meet-
ing, where patients’ self reports are collected, and in case it is nec-
essary, other clinical information is exchanged, sometimes in the 
form of brief advice and sometimes in a more informal manner. It 
was during these meetings that the nurse also provided her clinical 
judgment regarding the drinking status of the patient, in a qualita-
tive way (patient is totally abstinent: yes, no, unsure).
 We also collected information on whether patients were on di-
sulfiram or any another aversive medication, whether other sub-
stances were searched for in the urine sample, and if any of the 
co-screenings yielded positive results. Weekly frequency of urine 
testing (less than once weekly, once weekly or more than once 
weekly) was also collected.
 Statistical Analysis 
 Sociodemographic characteristics of the sample were described 
for all subjects who provided urine samples. Quantitative com-
parative analyses were performed between the rate of positive re-
sults of ethanol and the rate of positive results of EtG. In ethanol-
negative subjects, comparisons were conducted between subjects 
with positive or negative EtG, followed by regression analysis as a 
means to investigate if there were any features predicting the pos-
itivity of EtG. The detection performance of clinical judgment was 
further assessed using EtG as a gold standard to calculate the area 
under the receiving operator curve.
 Results 
 A total of 188 patients provided 613 consecutive urine 
samples, in a 14-days period.  Table 1 outlines the main 
sociodemographic characteristics of the sample.
Table 1.  Characteristics of the sample
Whole sample (n = 613), 
mean (SD) or %
EtG positive (n = 136), 
mean (SD) or %
EtG negative (n = 477), 
mean (SD) or %
Age, years 50 (11.8) 51.5 (10.6) 50 (12.1)
Duration of urine screening, years 3.2 (5.1) 4.2 (7.1) 2.9 (4.4)
Sex, male 69.6% 94 (69.1%) 332 (69.7%)
Co-screen 28.1% 32 (23.5%) 140 (29.4%)
Opioids 0.5% 0 (0%) 3 (0.6%)
Cocaine 9.3% 9 (6.6%) 48 (10.1%)
Cannabis 20.4% 23 (16.9%) 102 (21.4%)
Benzodiacepinas 8.2% 9 (6.6%) 41 (8.6%)
Amphetamines 12.6% 11 (8.1%) 66 (13.8%)
Positive to other substances 59 (9.6%) 16 (11.8%) 43 (9%)
Taking aversive medication 37.6% 33 (25%) 193 (41.2%)
Frequency of urine testing
Less than once weekly 6.6% 12 (9%) 27 (5.9%)
Once weekly 18.9% 18 (13.4%) 94 (20.4%)
More than once weekly 74.6% 104 (77.6%) 339 (73.7%)
Nurse judgment
Abstinent 535 (88.6%) 98 (74.2%) 437 (92.6%)
Not abstinent 48 (7.9%) 23 (14.4%) 25 (5.3%)
Unsure 15 (2.5%) 7 (5.3%) 8 (1.7%)
Patient self-discloses drinking 6 (1%) 4 (3%) 2 (4%)
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 Regarding the total number of positives, urinary etha-
nol resulted in 9 positive samples belonging to 8 patients. 
EtG yielded 136 positive samples belonging to 74 pa-
tients. Most EtG positive samples (125) were negative for 
alcohol. It means that 20.4% of the total urine samples 
(125/613) were discordant regarding EtG and ethanol. As 
expected, all urinary alcohol positives resulted in EtG 
positives.
 The percentage of co-screened samples for other 
substances was 28.1% (172/613). Cannabis was the main 
substance investigated, with 20.4% of the whole sample 
(125/613 urine samples), resulting in a 9.6% of posi-
tives when calculated for the total sample (59/613). EtG 
was positive in 14.6% of the samples of patients being 
on aversive medications and in 26.4% of patients who 
were not in treatment with aversive medication. The 
group being screened less than weekly resulted in a 
30.8% of positive EtG urine samples, those screened 
once weekly resulted in 16.1% positives and those 
screened more than once weekly resulted in 23.5% pos-
itive samples.
 In the logistic regression model, the following vari-
ables were entered: gender, age, duration and frequency 
of urine screening, co-screening to other substances, pos-
itive to other substances, clinical judgment and being on 
aversive medication. Of these variables, only being on 
aversive medication and clinical judgment resulted in sig-
nificant effects ( table 2 ).
 Regarding the diagnostic performance of the nurse, 
she judged 89.7% (550/613) of the samples, belonging to 
178 patients, as abstinent. She deemed 7.8% (48/613) of 
the samples, belonging to 26 patients, as not abstinent, 
and was unsure in 15 samples from 15 patients. When 
comparing it against EtG, it resulted in an area under the 
curve of 0.592.
 Discussion 
 In line with the data reported in previous experimen-
tal studies, the results of this study clearly indicate a rel-
evant difference in the detection capacity of urinary eth-
anol, self reports and urinary EtG. The discrepancy be-
tween the 2 metabolites (one yielding only 1.5% of 
positives, the other 22.2%) is so large that they depict 2 
different  realities.
 If we were to rely only on urinary ethanol, it would 
look like a great majority of our outpatients do exceed-
ingly well in an abstinence-oriented program, with less 
than 5% of patients drinking alcohol. On the other hand, 
if we consider data provided by EtG assessment, the pic-
ture is radically different. We no longer have a big popu-
lation of alcohol patients who cope with their alcohol 
problems in a way that they are able to maintain absti-
nence. We indeed have almost a 40% of patients who are 
not fully abstinent. And, importantly, were it not for EtG, 
we would not be aware of this huge proportion. In this 
study, self reports are even less reliable than ethanol. It is 
indeed well known that self-reports tend to underesti-
mate patients’ consumption rates  [27–30] .
 Since the introduction of EtG for urine screening in 
AUD patients, the studies conducted have almost univer-
sally found a higher detection rate of EtG, irrespective of 
the comparator employed  [22, 23, 31, 32] . Most of the 
studies have compared EtG to self-reports and breath al-
cohol, both with relevant caveats as screening elements 
for alcohol patients. Breath alcohol testing offers a short 
detection window, jeopardizing its validity as a detection 
instrument for recent alcohol consumption. In this sense, 
previous studies report even higher numbers than ours 
when it comes to discrepancies with EtG. For example, 
Mutschler et al.  [32] found in a group of 51 outpatients 
under supervised disulfiram a 59% discrepancy between 
EtG and breath alcohol testing. Similarly, Junghanns et al. 
 [14] found a 28% discrepancy between EtG and self re-
ports in 139 outpatients. The studies by Wurst et al.  [24] 
and Skipper et al.  [31] , in which EtG was compared to 
urinary alcohol, reported a discrepancy of 9 and 7%, re-
spectively.
 Regarding the analysis of the clinical variables and its 
relation to the EtG results, the strongest predictors of EtG 
positivity were clinical judgment and the presence of al-
cohol deterrent medications, such as disulfiram or calci-
um carbimide, thus reinforcing the perceived utility of 
these medications. While some of the patients received 
the medication supervised by the nurse, a majority of 
them took it at home. This fact might help explain the 
Table 2.  Independent variables in the logistic regression model
Parameter OR 95% CI Significance, 
p value
Nurse judgment 2 1.4–2.9 <0.001
Disulfiram 2.1 1.3–3.3 0.003
Weekly frequency 1.1 0.7–1.5 0.653
Positive to other drugs 2.2 0.9–4.9 0.062
Sex 0.9 0.6–1.5 0.885
Duration of screening 1.05 1.003–1.091 0.036
Age, years 1.01 0.985–1.03 0.653
 In this regression model, urinary EtG is considered the depen-
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high number of patients provided with deterrent medica-
tions that yielded an EtG positive (suggesting a low or no 
medication adherence). The rate of positives suspected by 
the nurse was halfway between those of EtG and urinary 
ethanol, suggesting that up to 10.5% of urine samples 
came from not abstinent patients. In fact, previous studies 
suggest clinicians are ill equipped when it comes to assess 
substance intake in their patients  [33] .
 One of the strengths of this study is its observational 
nature, a fact that allows for a more valid, less biased as-
sessment of reality. While experimental assessments are 
clearly indispensable, they are found to have various ca-
veats, such as assessment reactivity, Hawthorne’s effect, 
or even social desirability, all well-known biases to scien-
tific research  [34, 35] . 
The huge discrepancy found in this observational 
study leads to a pressing question: what is the real purpose 
of urine screening in these patients? Is it about regular 
control, relapse prevention and contingency manage-
ment? Or is it about education, habit-changing routines 
and continuous support? Or is it both? This area deserves 
further research.
 Taken together, the data provided in this study suggest 
that urinary EtG performs exceedingly well in real outpa-
tient settings, or at least much better than traditional di-
agnostic methods. What remains to be a matter of con-
cern is the fact that in real clinical settings, where routine 
urinary or breath screening is conducted aiming at re-
lapse prevention, we might be performing rather poor, 
even if we incorporate professionals’ expertise and judg-
ment into the equation.
 Despite its clear results, some limitations must be con-
sidered for this study. First, EtG positives are known to 
occur after the unintentional ingestion of alcohol via 
mouthwashes or the use of alcohol-containing hand san-
itizers. However, this might account only for a residual 
number of positives. Also, despite the fact that some pre-
vious research indicates that a cut-off of 500 ng/ml might 
produce a relative high risk of unintended positives  [36] , 
other recent studies suggest that the specificity of EtG re-
mains acceptably high with this cut-off  [37] . Also, EtG/
creatinine ratios and EtG-LC-MS/MS confirmation tests 
were not conducted. Nonetheless, recent studies  [11, 12, 
38] suggest that this is not necessary. Also, despite being 
an observational study with an expected high external va-
lidity, the results belong to a single center, a fact that 
might limit the generalization of our results. Finally, it is 
important to note that this is not a validation study of 
EtG. Therefore, many of the conclusions reached through-
out the paper are based on the assumption that EtG is the 
closest and most reliable assessment of reality when it 
comes to determining the drinking status of patients. 
While this study might not be able to provide direct evi-
dence supporting this claim, there is a notorious body of 
evidence that makes this inference reasonably valid.
 As a conclusion, the data displayed by this and other 
studies clearly suggest that a wide implementation of EtG 
in real settings would yield relevant improvements in the 
monitoring of abstinence in outpatient populations. It 
follows that relapse prevention would be significantly im-
proved. Further, research will have to specifically address 
this question, and investigate the clinical and economic 
consequences of implementing a high-detection capacity 
tool such as urinary EtG in alcohol disorders’ outpatients.
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Based on hypotehsis #2, and taking into account the results of Study 1, we aimed at 
evaluating one year correlates of an EtG positive urine screening, with special attention to relapse 
and the need of hospitalization. We also tried to estimate costs related to addiction treatment for 




After one year, the presence of relapse, the number of hospitalizations and whether patients 
had abandoned treatment or not were assessed from electronic medical records. A survival analysis 
was conducted to compare time to relapse between EtG negative and positive subjects. Regression 
models were performed to compare the mean number of days hospitalized between groups, the risk 
of being lost to follow-up and treatment expenses. 
Relapse was operationalized as meeting any of the following criteria: 
1) Need for total or partial (day hospital) hospitalization, or emergency department attendance, due 
to alcohol consumption. 
2) Positivity of a urine screening (performed with ethanol, since at the time of study procedures it 
was the routine method of screening in our site). 
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3) Clinical detection, according to patient’s medical record, of any alcohol consumption. This could 
be in the form of patient self-report, significant-others report or clinician report. 
Time until relapse was recorded. Other collected variables included the number of visits with 
an addiction professional that patients attended during the following year, the number of urine 
screenings performed and whether patients were lost to follow-up or not during this time. For 
economical evaluations, price per day of total or partial hospitalization and price per visit were 
obtained from the corresponding local agency. 
To compare the differential rate of relapse between EtG positive and EtG negative subjects, 
a survival analysis was performed. The endpoint was defined as relapse, according to the first 
occurring criteria of the operationalization described above. Kaplan-Meier survival curves were 
plotted and compared with the log-rank test. A Cox-regression model was further conducted, 
including age, sex, addictive comorbidities and length of urine testing in order to adjust the 
contribution of an EtG positive urine screening at baseline as an indicator of relapse risk during the 
following year. 
 To compare hospitalizations between EtG positive and negative groups, a multivariate 
regression analysis was conducted with the mean number of days of hospitalization as the 
dependent variable. For this purpose, days of complete hospitalization and days of partial 
hospitalization (day hospital) were added together. Independent variables included EtG status at 
baseline, sex, age, addictive comorbidities and length of urine testing. 
 For economical evaluations, a price per day of total and partial hospitalization was gathered 
from the pertinent local health agency. A price was also fixed for every outpatient visit that patients 
completed. A mean price for each group (EtG positive vs. EtG negative) was calculated. Also, a 
multivariate regression analysis was conducted with mean price as a dependent variable and EtG 
status at baseline, sex, age, addictive comorbidities and length of urine testing as independent 
predictors.   
Finally, the rate of patients lost during the next year was compared between EtG groups with 
binary logistic regression incorporating age, sex, addictive comorbidities and length of urine testing 
as independent variables. 
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 In order to test whether other factors could replicate the prediction capacity of EtG, all 
models were performed again substituting EtG results by clinician judgment. Given the outlying few 
positive self-reports we had in the initial study, the use of this variable for another set of analysis was 




At baseline, data was extracted from 185 patients, of which 33 were excluded from analysis 
since they were considered to be actively and overtly drinking. This could be because they had a 
positive ethanol result at baseline, because their self-report was positive or because the treating 
clinician had clearly identified the patient was actively drinking in that period of time. Since the main 
objective of the present paper was the survival analysis, they were excluded because they were 
considered to have already reached the endpoint before study initiation.  
 The Kaplan-Meier curves comparing EtG positive and negative groups were clearly 
different. The Log-Rank test revealed significant differences (chi=58,382 df=1; p<0,001). The mean 
survival time of EtG positive subjects was 163 days, compared to 329 days in those with a negative 
result. In the Cox regression model, only EtG positivity yielded significant results, with a hazard ratio 
of 5,3 (95%CI: 3,1 to 9,1). The positive predictive value of EtG regarding relapse risk was 0,8. The 
negative predictive value was 0,76. 
 In the comparison between hospitalizations, the multivariate regression analysis confirmed 
the significance of a positive EtG result at baseline as a predictor of increased number of days 
hospitalized, with b=5,3 (95%CI: 2,1 to 8,4). The rest of the covariates were non-significant. 
 For economical evaluations, the following prices were established according to the local 
health agency recommendations: day of total hospitalization: 555 €, day of partial hospitalization 
(day hospital): 117 €, outpatient visit with an addiction professional: 137 €. Calculations yielded a 
mean cost of 2.167 € for EtG positive patients, and 566 € for EtG negative patients. In the regression 
analysis, only EtG status was a significant predictor. 
43 
 
 Finally, in the binary logistic regression conducted to investigate factors associated with the 
risk of being lost to follow-up during the year following EtG testing, EtG positivity was significant in 
the univariate analysis, but only age was a significant predictor in the final, multivariate model, being 
older associated with a lesser risk of discontinuing treatment (OR= 0,94, 95%CI: 0,89 to 0,98). 
 When substituting EtG for clinician judgment, none of the models found a significant 
contribution of this variable. The survival curves according to the different clinician judgment 




EtG positive subjects have a clearly differentiated evolution in the following year. It means 
EtG might help clinicians to identify early signs of relapse, and therefore it could also allow them to 
early address it, making the whole process more efficient. Also, it looks like the positive predictive 
value of EtG could allow for a better targeting of those patients that are in need of a more urgent, 
intense intervention, while, at the same time, the negative predictive value of EtG could reassure 
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Abstract
Aims: Little evidence exists supporting the efficacy of regular alcohol urine screening (RAUS) in
the management of alcohol dependence, despite recent improvements in urine biomarkers. In this
study, we aimed at investigating 1 year, differential clinical correlates between a positive and a
negative baseline urine ethyl glucuronide (EtG) screening.
Methods: Alcohol-dependent outpatients participating in a previous cross-sectional study where
EtG and ethanol diagnostic performances were compared in a double blind design were included.
After 1 year, the presence of relapse, the number of hospitalizations and whether patients had
abandoned treatment or not were assessed from electronic medical records. A survival analysis
was conducted to compare time to relapse between EtG negative and positive subjects.
Regression models were performed to compare the mean number of days hospitalized between
groups, the risk of being lost to follow-up and treatment expenses.
Results: Of note, 152 patients (mean age 52, 67% males) were included. The mean time to relapse
was of 163 days in EtG positive subjects, compared to 329 days in those with a negative result. In
the Cox-regression model, only EtG positivity yielded significant results, with a hazard ratio of 5:3
(95% CI: 3.1–9.1). EtG positive was also the only significant predictor of a greater number of hospi-
talization days and treatment expenses. Younger age was the only variable predicting a greater
risk of treatment abandonment.
Conclusion: RAUS with sensible biomarkers could improve clinicians’ ability to assess patients’
relapse risk. Further prospective studies will have to determine if this can be translated into a bet-
ter prevention capacity.
Short summary: Positive urine screenings, when conducted with highly sensible alcohol biomar-
kers, significantly indicate a greater risk of relapse in alcohol-dependent patients and have the
capacity to predict a greater risk of hospitalization and greater treatment expenses.
© The Author 2017. Medical Council on Alcohol and Oxford University Press. All rights reserved 1
INTRODUCTION
Alcohol is one of the leading drivers of harm worldwide (Whiteford
et al., 2013; Christopher and Murray, 2016). Its consequences affect
both individuals and societies as a whole (Barrio et al.; in press).
Individuals causing the greatest part of this harm are those who are
dependent on it (Mohapatra et al., 2010). Therefore, alcohol
dependence should be considered as a top priority from a public
health perspective (WHO, 2014).
The proper management of alcohol dependence requires the use
of several strategies, from psychosocial to pharmacological ones.
One frequently used element, especially in abstinence oriented set-
tings, is regular alcohol urine screening (SAMHSA 2012; American
Society of Addiciton Medicine, 2014). Traditional markers used for
this purpose remain suboptimal with regard to sensitivity and speci-
ficity, especially when it comes to detecting recent drinking. Ethanol
remains detectable only for ~8–12 h post ingestion, whereas other
traditional markers such as gamma glutamyltransferase, mean cor-
puscular volume or carbohydrate deficient trasnferrin need persist-
ent consumption of higher amounts of alcohol (>2 weeks, >1000 g
of ethanol in 2 weeks) to become elevated.
Fortunately, in recent years there has been a noticeable improve-
ment in the sensibility and specificity of biomarkers of alcohol con-
sumption, with the appearance of more sensible and specific markers,
such as ethyl glucuronide (EtG), ethyl sulfate or phosphatidylethanol
(Wurst et al. 2015). They all expand the time window for the detec-
tion of recent alcohol consumption in urine samples. This might offer
relevant improvements in clinical practice, in as much as covert
drinking might be more frequently detected and so earlier addressed,
Up to date, EtG has the advantage of an existing commercially avail-
able enzyme immunoassay (EIA) method based on a new monoclonal
antibody (Diagnostic Reagents Incorporated-EtG EIA, Thermo
Fisher Scientific Diagnostics, Hemel Hempstead, UK), that allows for
a more cost-effective detection of EtG in urine samples. However,
despite the wide use of frequent urine screening and the recent
improvements in its biomarkers, little evidence exists supporting its
clinical efficacy in alcohol dependence (Dupouy et al. 2014).
In a recent cross-sectional study (Barrio et al. 2016), we found
that under routine clinical conditions, EtG performed largely better
than ethanol, self-report and clinical judgment in the detection of
recent drinking. In fact, a solid body of evidence demonstrates that
EtG performs largely better than self-reports and ethanol in the
detection of recent drinking (Wurst et al., 2004; Junghanns et al.,
2009; Dahl et al., 2011; Jatlow et al., 2014; Leickly et al., 2015).
Given that both patients and clinicians were unaware of EtG results
and that patients were followed-up as part of their usual treatment
during the following year, and subsequent urinary assessments were
done with ethanol, we had the opportunity to assess the differential,
1-year correlates of a baseline EtG positive urine screening. We
believe that this is a relevant issue, since it allows for a more detailed
and precise delineation of what is really a positive urine screening
with a highly sensible biomarker telling us, when we face an alcohol
addicted patient with regard to risk of relapse, risk of hospitalization
and what its economic implications are, something that has not been
previously studied. It must be noted that subsequent urinary assess-
ments were performed with ethanol instead of EtG because ethanol
was the routine marker used in our laboratory, and during the study
period, we had not the chance to routinely utilize EtG as a marker
of alcohol consumption.
While there is a solid body of evidence assessing the predictive
capacity of other variables such as illness severity (Langenbucher
et al., 1996), craving (Bottlender and Koyka, 2004), DSM-IV cri-
teria (Fazzino et al., 2014) or other psychological constructs such as
persistence and self-efficacy (Cannon et al., 1997) when trying to
determine the risk of relapse, there is no such literature related to
the predictive capacity of urine screenings. And the same happens
when analyzing the risk of hospitalization (Lawder et al., 2011;
Hong et al., 2014; Chang et al., 2016). The objective of the present
study was to analyze 1-year correlates of a EtG positive urine
screening, with special attention to relapse and the need of hospital-
ization. We also tried to estimate costs related to addiction treat-
ment for both EtG and EtG negative subjects in the following year.
MATERIALS AND METHODS
Subjects
Participants were previously recruited in a study comparing the per-
formance of urinary EtG in routine clinical conditions (Barrio et al.,
2016). Subjects were adult alcohol-dependent patients receiving
treatment in an outpatient department from a big tertiary urban
hospital in Barcelona. In the initial study, in a cross-sectional
design, patients were tested for both ethanol and EtG in their urine,
incorporating also patients’ self-reports and the judgment of the
attending nurse. Patients were unaware of EtG testing, and the
results obtained were not available to their treating clinicians. For
the present study, patients were divided into two cohorts, those who
screened positive for EtG and those who screened negative for EtG.
Patients that were actively and overtly drinking at baseline were
excluded from this study, since they could not be incorporated into
the main survival analysis. Ethics approval was granted from the
Clinic Hospital of Barcelona IRB (decision number HCB/2015/
0984).
Measurements
Basic sociodemographic and clinical data, as well as the baseline
value of urinary EtG, were extracted from the previous study. One
year after the study was completed, electronic medical records from
participants were reviewed for data collection and analysis. The
number of total or partial hospitalizations (day hospital) was
recorded.
The main outcome of the study was defined as relapse, which
was operationalized as meeting any of the following criteria:
(1) Need for total or partial (day hospital) hospitalization, or emer-
gency department attendance, due to alcohol consumption.
(2) Positivity of a urine screening (performed with ethanol).
(3) Clinical detection, according to patient’s medical record, of any
alcohol consumption. This could be in the form of patient self-
report, significant others report or clinician report.
Time until relapse was also recorded. Other collected variables
included the number of visits with an addiction professional that
patients attended during the following year, the number of urine
screenings performed and whether patients were lost to follow-up or
not during this time. For economical evaluations, price per day of
total or partial hospitalization and price per visit were obtained
from the corresponding local agency.
Statistical analysis
To compare the differential rate of relapse between EtG positive and
EtG negative subjects, a survival analysis was performed. The
2 Alcohol and Alcoholism
endpoint was defined as relapse, according to the first occurring cri-
teria of the operationalization described above. Kaplan–Meier sur-
vival curves were plotted and compared with the log-rank test. A
Cox-regression model was further conducted, including age, sex,
addictive comorbidities and length of urine testing in order to adjust
the contribution of an EtG positive urine screening at baseline as an
indicator of relapse risk during the following year.
To compare hospitalizations between EtG positive and negative
groups, a multivariate regression analysis was conducted with the
mean number of days of hospitalization as the dependent variable.
For this purpose, days of complete hospitalization and days of par-
tial hospitalization (day hospital) were added together. Independent
variables included EtG status at baseline, sex, age, addictive
comorbidities and length of urine testing.
For economical evaluations, a price per day of total and partial
hospitalization was gathered from the pertinent local health agency.
A price was also fixed for every outpatient visit that patients com-
pleted. A mean price for each group (EtG positive vs EtG negative)
was calculated. Also, a multivariate regression analysis was con-
ducted with mean price as a dependent variable and EtG status at
baseline, sex, age, addictive comorbidities and length of urine testing
as independent predictors.
Finally, the rate of patients lost during the next year was com-
pared between EtG groups with binary logistic regression incorpor-
ating age, sex, addictive comorbidities and length of urine testing as
independent variables.
In order to test whether other factors could replicate the predic-
tion capacity of EtG, all models were performed again substituting
EtG results by clinician judgment. Given the outlying few positive
self-reports we had in the initial study, the use of this variable for
another set of analysis was deemed inappropriate.
Data were analyzed using SPSS 21.0 (SPSS Inc., Chicago,
Illinois). Ethanol measurement in urine was performed with molecu-
lar absorption spectroscopy.
RESULTS
At baseline, data were extracted from 185 patients, of which 33 were
excluded from analysis since they were considered to be actively and
overtly drinking. This could be because they had a positive ethanol
result at baseline, because their self-report was positive or because the
treating clinician had clearly identified the patient was actively drinking
in that period of time. Since the main objective of the present paper
was the survival analysis, they were excluded because they were con-
sidered to have already reached the endpoint before study initiation.
Basic sociodemographic characteristics of both groups and clinical
data gathered during the 1-year follow-up are compared in Table 1.
The Kaplan–Meier curves comparing EtG positive and negative
groups are displayed in Fig. 1. The log-rank test revealed significant
differences (chi = 58.382 df = 1; P < 0.001). The mean survival
time of EtG positive subjects was 163 days, compared to 329 days
in those with a negative result. In the Cox-regression model, only
EtG positivity yielded significant results, with a hazard ratio of 5:3
(95% CI: 3.1–9.1).
In the comparison between hospitalizations, the multivariate
regression analysis confirmed the significance of a positive EtG result
at baseline as a predictor of increased number of days hospitalized,
with b = 5.3 (95% CI: 2.1–8.4). The rest of the covariates were
non-significant.
For economical evaluations, the following prices were estab-
lished according to the local health agency recommendations—day
of total hospitalization: 555 €; day of partial hospitalization (day
hospital): 117€; outpatient visit with an addiction professional:
137 €. Calculations yielded a mean cost of 2.167 € for EtG positive
patients, and 566 € for EtG negative patients. In the regression ana-
lysis, only EtG status was a significant predictor.
Finally, in the binary logistic regression conducted to investigate
factors associated with the risk of being lost to follow-up during the
year following EtG testing, EtG positivity was significant in the uni-
variate analysis, but only age was a significant predictor in the final
model, being older associated with a lesser risk of discontinuing
treatment (OR = 0.94, 95% CI: 0.89–0.98).
When substituting EtG for clinician judgment, none of the mod-
els found a significant contribution of this variable. The survival
curves according to the different clinician judgment (abstinent vs
non-abstinent) are displayed in Fig. 2 (log-rank test not significant;
chi = 3264 df = 1; P = 0.071).
DISCUSSION
In this study, we evaluated 1-year clinical correlates of a positive
baseline EtG urine screening, as compared to a negative baseline
result. Both patients and clinicians were unaware of baseline EtG
results. Also, since we could not incorporate EtG testing as our rou-
tine biomarker due to budget and time constraints in the following
year, the ongoing urine screenings were performed with ethanol.
This in fact allowed the performance of the present study, where the
implications of a single EtG testing could be evaluated. The data
obtained during the follow-up suggest that patients testing positive
in EtG will have a different clinical evolution in the following year,
with a significant increase in relapses, hospitalizations and treatment
expenses. Given that both patients and clinicians were unaware of
EtG status at baseline, one pressing question emerges: could some of
this differences have been avoided, was this information made avail-
able to them? Although such a question cannot be answered by this
study, and needs for prospective, randomized investigations, we
believe some clues can be drawn from our data.
Although the need for hospitalization for the whole sample was
rather low, with only 10 patients (6.6% of the total sample) requir-
ing it, the differences between groups were both significant and
large, with only one patient in the EtG negative arm being hospita-
lized in the following year. Taking a stepped care approach, hospi-
talization could be considered as one of the final steps in dealing
with a relapse, which might have been initiated much before in the
form of lapses. This might be a crucial point in time where the use
of sensible alcohol biomarkers such as EtG could help to identify the
beginning of the relapse, and so to earlier address it, with the poten-
tial impact of avoiding the need for hospitalization and also of redu-
cing treatment expenses.
Though at first glance suggesting that patients who test positive
for EtG will relapse at a higher rate than those who do not could
seem tautological, this fact deserves further elaboration. First, one
should notice that relapse, though widely used as a concept, lacks
firm and conclusive criteria (Maisto et al., 2016), a fact that could
explain that being EtG positive does not immediately imply a
relapse. In fact, a minority of patients tested positive for EtG and
were clinically deemed as non-relapsed during the following year.
That being said, our data robustly show that an EtG positive dra-
matically increases the risk of having a clinical correlate in the fol-
lowing year, as shown by the hazard ratio obtained in the survival
analysis. In other words, patients testing positive for EtG will, with
very high probabilities, ultimately have clinical symptoms of relapse.
3Alcohol and Alcoholism
Therefore, an EtG positive screening could be considered as an early
relapse sign. But also looked the other way around, it looks like hav-
ing an EtG negative screening has a strong negative predictive value,
that is, it should reassure clinicians regarding patients’ favorable
evolution, at least in alcohol-related outcomes.
Our results are in line with previous, similar studies. For
example, Junghanns et al. (2009), found out that positive EtG urine
screening early after discharge significantly increased the rate of sub-
sequent relapse in recently discharged alcohol-dependent patients.
Similarly, Dahl et al. (2011) found EtG to be a useful and reliable
ongoing monitoring tool in alcohol treatment studies, specially sug-
gesting that an initial EtG negative sample is useful to confirm self-
reports.
Treatment expenses were clearly different between groups, dri-
ven both by the different number of days of hospitalization in both
cohorts as well as an increased number of visits in those EtG posi-
tive. In fact, it has already been shown that patients actively drink-
ing incur in greater costs (Aldridge et al., 2016; Witkiewitz and
Horn, 2016; Miquel et al., 2017). Although it was not included in
the cost analysis, it is worth mentioning that EtG positive patients
had also much more frequent urine testing during the follow-up. All
these data suggest that the implementation of EtG could also have
an economic impact in the treatment of alcohol dependence.
Regarding the capacity of predicting the risk of being lost to
follow-up, EtG showed significant results in the univariate analysis,
which seemed to disappear once age was included in the multivariate
Table 1. Sociodemographic and clinical data comparison between groups
Characteristic EtG negative (n = 102) EtG positive (n = 50) Whole sample
Age: mean (SD) 51.6 (10.3) 50.8 (11.5) 51.2 (10.7)
Gender: % of males 70 (69.3%) 31 (62%) 101 (66.9%)
Addictive comorbidities 36 (35.3%) 15 (30%) 51 (33.6%)
Benzodiacepines 10 (9.8%) 8 (16%) 18 (11.8%)
Cocaine 15 (14.7%) 3 (6%) 18 (11.8%)
Opiates 3 (2.9%) 0 (0%) 3 (2%)
Cannabis 28 (27.5%) 8 (16%) 36 (23.7%)
Length of urine screening (in months) 26.3 (34.6) 57.4 (74.6) 36.4 (53.2)
Number of patients requiring hospitalization: n (%) 1 (0.9%) 9 (18%) 10 (6.6%)
Days of hospitalization (adding up the count for all patients) 29 302 331
Number of visits with an addiction professional: mean (SD) 3.81 (2.4) 5.1 (2.7) 4.3 (2.6)
Number of urine screenings: mean (SD) 29.8 (26.4) 50.4 (32.5) 36.6 (30)
Number of patients relapsing: n (%) 24 (23.5%) 40 (80%) 64 (42.1%)
Number of patients lost to follow-up: n (%) 18 (17.6%) 16 (32%) 34 (22.4%)
Fig. 1. Survival curves plotted with the Kaplan–Meier method for EtG results.
Survival curves (in days) of both EtG positive (lower curve) and negative (upper curve) patients, with relapse considered the endpoint.
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model. In fact, previous literature already pointed out at older age as
a predictor of treatment retention (Korte et al., 2011; Haug and
Schaub, 2016). That being said, prior literature also consistently
shows that patients actively using alcohol or drugs are at a greater
risk of becoming non-treatment adherent (White et al., 2014;
Campbell et al., 2016; Haug et al., 2016). Also, previous studies with
EtG (Junghanns et al., 2009) have found that testing EtG positive
increases the risk of being lost to follow-up. Therefore, it would not
be unwise to consider EtG as a potentially useful tool in predicting the
risk of treatment abandonment.
Taken together, we believe that the data gathered by this study
has important implications for real practice. Although, as previously
acknowledged, there exist many other variables with a demonstrated
predictive capacity in alcohol-dependent patients regarding relapse
risk and general outcome, it looks like the implementation of EtG in
routine urine screening could improve clinicians capacity to detect
early signs of relapse, and therefore it would also allow them to
early address it, making the whole process more efficient. Also, it
looks like both the positive and negative predictive values of EtG
could allow for a better targeting of those patients that are in need
of a more urgent, intense intervention. It means that an EtG positive
patient should raise clinicians awareness and efforts immediately,
while an EtG negative patient could reassure them of a favorable
evolution, at least in the following months. Again, it is important to
state that urine screening should not be a substitute of other assess-
ments. However, in this study, we found it to be the most accurate,
precise predictor, even when controlling for other variables such as
age, sex, addictive comorbidities or length of urine testing, and also
clearly better than clinical judgment.
Several limitations should be noticed when interpreting our
study. First, data were gathered at the end of follow-up, which
means that variables were collected retrospectively. Importantly,
there exists the possibility that patients were hospitalized in other
centers, which could have biased our data. However, it would be
reasonable to consider that in both groups more hospitalizations
would have been seen, and probably even more in the EtG positive
patients. Therefore, this bias would result in an infraestimation of
EtG prediction capacity, which as we showed, turn out to be already
significant. Related to this, it is the fact that more EtG positive
patients were lost to follow-up. While survival analysis specifically
addresses this data, when analyzing days of hospitalization and
relapse risk, they had to be considered as missing data. However, as
previously mentioned, treatment abandonment has been associated
with increased relapse risk; therefore, it is probable that this missing
data turned out into an infraestimation of EtG prediction capacity
regarding relapse risk and hospitalization risk. Also relevant to men-
tion is the fact that relapse as an outcome was operationalized
according to different criteria, a fact that could limit the validity of
our results. Finally, it is important to note that psychiatric
comorbidities, a frequent phenomenon in alcohol-dependent
patients (Flensborg-Madsen et al., 2009; Fein, 2015), were not sys-
tematically recorded in this study, and therefore, their contribution
to the results obtained could not be evaluated.
All in all, we believe our study increases the available evidence
supporting the usefulness and clinical impact of regular urine screen-
ing in alcohol treatments. Though no efficacy data could be directly
inferred from our data, it looks like a wide implementation of sens-
ible alcohol biomarkers could help to improve the prediction cap-
acity of clinicians, especially in abstinence oriented settings. Further
prospective studies will have to examine whether this increased pre-
diction capacity can be translated into a greater treatment efficacy,
probably due to a better prevention.
Fig. 2. Survival curves plotted with the Kaplan–Meier method for clinical judgment.
Survival curves (in days) of both patients with positive (lower curve) and negative (upper curve) clinician judgment, with relapse considered the endpoint.
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Based on hypotheses #3 and #4, we aimed at  investigating if regular alcohol urine 
screening serves other purposes beyond abstinence monitoring, what attitudes patients display 




We conducted a cross-sectional survey among adults with alcohol dependence attending 
outpatient alcohol dependence treatment. It aimed at investigating patients’ attitudes and beliefs 
towards regular alcohol urine screening, and technical notions of alcohol urine screening. For 
attitudes’ assessment, we adapted the Drug Attitude Inventory (DAI-10) to the field of alcohol urine 
screening. Internal consistency, test-retest reliability and concurrent validity were evaluated for the 
adapted questionnaire. For technical knowledge assessment we used multiple-choice and Likert-
type questions.  
Regarding the adapted version of the DAI-10, an internal consistency analysis was carried 
out with Cronbach’s alpha. Concurrent validity was assessed via correlation between the DAI-10 
total score and a 0 to 10 Likert scale measure assessing the overall perceived value of urine 
screening as part of patients’ treatment. 
In order to evaluate if attitudes were influenced by any specific variable, we conducted a 
linear regression model with DAI-10 scores as the dependent variable and age, sex, level of 
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instruction, therapeutic objective, person taking the decision of attending the screening program and 
length of urine testing as independent variables. A subset of patients was asked to undertake the 
test again two to four weeks apart, to assess test-retest reliability for the DAI-10 scores. For that 
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(SD=2). Their correlation with mean DAI-10 score was of r=0,254, with p=0,009. Regression analysis 
could not find any significant predictor for test scores. Besides relapse prevention, patients 
frequently reported other functions such as showing professionals and family members that they 
don’t drink or having a closer contact with professionals. A majority of patients believed alcohol use 
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besides relapse prevention, other functions related to therapeutic alliance building, social desirability 
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Patients’ Knowledge and Attitudes Towards Regular
Alcohol Urine Screening: A Survey Study
Pablo Barrio, MD, Lı́dia Teixidor, BSN, Lluisa Ortega, MD, Mercè Balcells, PhD,
Eduard Vieta, PhD, and Antoni Gual, PhD
Background: Despite its wide implementation, there is a paucity of
data supporting the effectiveness of regular alcohol urine screening
(RAUS) in maintaining abstinence. This study aims at investigating if
RAUS serves other purposes, what attitudes patients display towards
it, and patients’ technical knowledge about basic screening notions.
Method: We conducted a cross-sectional survey among adults with
alcohol dependence, attending outpatient alcohol-dependence treat-
ment. It aimed at investigating patients’ attitudes and beliefs towards
RAUS, and technical notions of alcohol urine screening. For attitude
assessment, we adapted the Drug Attitude Inventory (DAI-10) to the
field of alcohol urine screening. Internal consistency, test-retest
reliability, and concurrent validity were evaluated for the adapted
questionnaire.
Results: In all, 128 patients completed the questionnaire. Patients
rated RAUS as high. The DAI-10 mean score was 7.2 (SD¼ 3.6).
Internal consistency analysis revealed a Cronbach alpha of 0.718.
Test-retest reliability evaluation yielded an intraclass correlation
coefficient of 0.932. The score of a single Likert-type question about
overall perceived value was 8.5 (SD¼ 2). Their correlation with
mean DAI-10 score was of r¼ 0.254, with P¼ 0.009. Apart from
relapse prevention, patients frequently reported other functions such
as showing professionals and family members that they do not drink,
or having a closer contact with professionals. A majority of patients
believed alcohol use goes undetected after 48 hours from last
ingestion.
Conclusion: Regular alcohol screening is highly valued by alcohol
outpatients. It seems that apart from relapse prevention, other
functions related to therapeutic alliance building, social desirability,
and impression management also play a key role.
Key Words: alcohol, attitudes, ethylglucuronide, survey, urine
screening
(J Addict Med 2017;xx: xxx–xxx)
A lcohol remains a first-order global health problem, with15 million people affected in the European Union
(Wittchen et al., 2011). Its consequences to individuals and
society are of an enormous dimension, the majority being
attributable to the severest form of alcohol use, namely
alcohol dependence (Mohapatra et al., 2010). It is currently
considered a chronic disease, with a relapsing-remitting
nature (Miller et al., 2001; Merkx et al., 2011). Despite some
controversies in the field (Gastfriend et al., 2007; Heilig et al.,
2011; Luquiens et al., 2011), abstinence has been the prevail-
ing therapeutic goal in most of the existing settings, being
considered the safest and most efficient pathway to early
recovery (Owen and Marlatt, 2001; Cox et al., 2004). There-
fore, for a great majority of professionals dealing with alcohol
dependence, monitoring abstinence is a task of paramount
importance.
Professionals dispose mainly 2 types of tools to under-
take this salient job. First, patients’ self-reports. For many
years, they were, apart from clinicians’ judgment, the only
available instrument. Despite all the advances in biological
markers, they remain a key component of routine clinical care
in many settings (Del Boca and Darkes, 2003). Nonetheless,
they suffer from some important pitfalls, especially regarding
their sensitivity in detecting alcohol consumption. Some of
the reasons underlying this shortcoming might be cognitive
deficits, fear of putting treatment in danger, fear of legal
consequences, or social desirability (Zemore, 2012). Some of
these might be overcome with alcohol biomarkers. They
should not be considered substitutes of self-reports, but rather
a complementary element that might yield important contri-
butions in different situations, such as outcome measures in
research studies, screening for alcohol problems in individ-
uals unable to provide accurate self- reports, or an instrument
to monitor abstinence (SAMHSA, 2012).
Alcohol biomarkers can be obtained from a variety of
sources. Blood, breath, and urine are the most common.
Whereas some of them should be considered markers of
heavy use over time, others are better suited for abstinence
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monitoring. For example, traditional markers such as gamma-
glutamyl transferase (GGT) or mean corpuscular volume
(MCV) need prolonged ingestion of relatively high amounts
of alcohol to become elevated (Mihas and Tavassoli, 1992;
Conigrave et al., 1995). Even carbohydrate-deficient trasn-
ferrin (CDT), which certainly improves the specificity of
traditional biomarkers, requires at least a few drinks a day
for 2 weeks to become elevated (Hock et al., 2005). Hence,
they do not seem feasible candidates for a proper abstinence
monitoring system, since they would be unable to detect
single lapses or short-term relapses. Moreover, they are
measured in blood, a fact that limits its usefulness as a routine
screening method.
In this sense, urine offers some relevant advantages over
blood in routine clinical practice, especially when patients
have to undergo frequent testing. Regular urine screening for
abstinence monitoring is indeed a frequent practice in many
abstinence-oriented settings (American Society of Addiction
Medicine, 2010). So far, urinary ethanol has been the main
marker used. Similar to breath alcohol testing, it only remains
positive for a few hours after alcohol ingestion, thus preclud-
ing a proper monitoring of abstinence (Helander and Eriksson,
2002). Fortunately, in the field of alcohol biomarkers, some
recent advances display promising features, which could
allow the overcoming of some of the previously mentioned
shortcomings. Especially, ethylglucuronide (EtG), a water-
soluble, direct metabolite of alcohol, which remains detect-
able in urine up to 72 hours after the ingestion of even a single
drink (Lowe et al., 2015). In a recent study, Barrio et al. (2016)
demonstrated an over-riding superiority of EtG over ethanol
in the detection of recent drinking in an abstinence-oriented
setting. Despite the intuition that a higher detection capacity
would translate into more efficacious and efficient clinical
care, there is a paucity of data addressing this question. A
recent systematic review (Dupouy et al., 2014) found little
evidence in favor of the clinical utility of conducting urine
drug screening, outlining that only a few, ill-powered studies
have directly addressed this question. Taking our previous
research into account, it became also evident that conven-
tional urine screening for alcohol outpatients is far from
satisfactory in monitoring abstinence. In assessing this fact,
some related questions seemed to emerge: what are the
reasons underlying this poor effectiveness? Does urine screen-
ing serve other functions besides monitoring abstinence, such
as offering ongoing support? What do patients know about
urine screening, and what are their attitudes towards it?
In this study, we try to unravel some of the answers to
these questions by focusing mainly on 2 aspects: first,
patients’ knowledge about urine-screening elements and tech-
niques, with a special focus on detection times, aiming at
discerning if it could partly explain the low effectiveness of
ethanol urine screening previously reported. Second, we aim
at investigating patients’ attitudes and beliefs about urine
screening, to obtain patients’ perspectives on the motives
and perceived usefulness of such technique. It is important
to remember that, in line with the increasing importance of
patient-centered care as a central tenet of high-quality health-
care delivery (Institute of Medicine., 2001), also in the field of
alcohol dependence (Bradley and Kivlahan, 2014; Barrio and
Gual, in press), patients always have a unique perspective on
any service or intervention they receive. Hence, their input
becomes an essential component of service evaluation and
improvement. Whereas there are multiple surveys among
professionals regarding urine drug screening (Reisfield
et al., 2007; Pergolizzi et al., 2010; Owen et al., 2012; Starrels
et al., 2012; Kirsh et al., 2015), to the best of our knowledge,
this is the first time that patients become the target population
of the survey.
METHODS
Study Design and Subjects
We performed a cross-sectional survey among adult,
alcohol-dependent patients attending the outpatient service of
the Addictive Behaviors Unit at the Clinic Hospital of Bar-
celona. Eligible participants were those who attended regular
urine screening as part of their usual treatment. The nurse
responsible for receiving patients and storing their urine
specimens consecutively offered them to participate in the
study. No compensation existed for study completion. The
local ethics committee granted study approval.
Instrument
Questionnaires, along with focus groups, semistruc-
tured interviews, and patient shadowing, are one of the main
instruments to collect patients’ views (Domecq Garces et al.,
2012). For this study, a specific questionnaire was designed.
Four psychiatrists, 1 addiction nurse, 2 psychologists, and 1
social science expert took part in its design. The questionnaire
consisted of 3 main parts. The first was devised to gather basic
sociodemographic characteristics. The second one was aimed
at evaluating patients’ knowledge regarding technical aspects
of urine drug screening. It consisted of 3 multiple-choice
questions related to general concepts of screening, such as
basic pharmacokinetic notions, alcohol metabolites, and its
detection window. The third part was designed to obtain
patients’ beliefs and attitudes towards urine screening as part
of their treatment. The methodology employed in this section
was mainly that of multiple-choice questions and Likert-scale
responses to affirmations related to possible patients’ atti-
tudes. Also, given the lack of similar research for this specific
subject, we took advantage of the extensive literature regard-
ing the Drug Attitude Inventory-10 (DAI-10) (Hogan et al.,
1983), which was initially designed to test the attitudes of
patients with schizophrenia towards medication to correlate it
to medication adherence. It consists of 10 items, each one of
which is scored with either 1 or1, depending on whether the
response signals a good attitude towards medication or not. To
avoid response bias, half of the items are worded positively,
and half negatively. Its score ranges from 10 to 10. We
adapted its 10 items to the field of alcohol urine screening,
replacing the concept of medication by that of regular alcohol
urine screening (RAUS). While this adaptation of the DAI-10
lacks previous validation, a former study with alcoholic
patients attending Alcoholic Anonymous performed a similar
adaptation, showing good psychometric properties (Terra
et al., 2011). Also, we still considered it a good approach
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to capture patients’ attitudes, given the lack of more specific,
validated instruments for our study aims.
In the design of multiple-choice questions, authors
initially provided several responses in a brain-storming phase.
This initial pooling of possible responses was based both on
literature searches from all of the authors, and also their
personal expertise in the field. Once all authors agreed that
all possible and meaningful responses were present, a con-
sensus process was initiated to narrow the options to the most
relevant, keeping in mind the importance of covering all
possible responses to avoid biases and at the same time trying
to keep the questions short and simple to facilitate question-
naire comprehension and increase response rates. Once all
questions with its multiple options were finalized, they were
shared with 2 external psychiatrists and 1 psychologist, who
suggested minor changes.
Once designed, the authors analyzed the linguistic
aspects of the questionnaire, and the necessary amendments
were made to improve its understandability. Face and content
validity was also evaluated by authors and external experts on
the field. The complete questionnaire can be seen in Figure 1.
Procedure
The professional responsible for receiving patients and
their urine specimens, an experienced nurse in the addiction
field, consecutively in a 2-week period, offered patients the
possibility of taking the questionnaire. Patients with cognitive
decline (based on the nurse clinical judgment) or any other
condition, which, in the opinion of the investigators, could have
compromised the validity of responses, were not offered to
participate. Patients were reassured that all data provided would
be kept totally anonymous. Once completed, questionnaires
were kept safe until study end, when they were all analyzed.
Statistical Analysis
A descriptive analysis of sociodemographic data was
conducted. The mean and the standard deviation (SD) were
used for continuous variables; percentages were used for
qualitative variables. Regarding the adapted version of the
DAI-10, an internal consistency analysis was carried out with
Cronbach alpha. Concurrent validity was assessed via bivari-
ate correlations between the DAI-10 total score and a 0 to 10
Likert scale measure assessing the overall perceived value
of urine screening as part of patients’ treatment. These 2
measures were also compared between patients attending
twice per week and those with less frequent attendance to
the screening program, with independent t test calculation, to
evaluate if a more regular attendance could influence patients
attitudes and overall perceived value. Finally, to evaluate if
attitudes were influenced by any specific variable, we con-
ducted univariate correlations between DAI-10 scores and
age, sex, level of instruction, therapeutic objective, person
taking the decision of attending the screening program, and
length of urine testing. Finally, all variables were introduced
into a lineal regression model. A subset of patients was asked
to undertake the test again 2 to 4 weeks apart, to assess test-
retest reliability for the DAI-10 scores. For that purpose, we
calculated the intraclass correlation coefficient, based on
absolute agreement and a 2-way mixed-effects model.
RESULTS
During the study period, 160 patients were approached,
of which 128 accepted and completed the questionnaire. The
mean age of the sample was 54 years (SD¼ 10.9). The
majority (67.5%) were men, and 41.7% of the sample was
currently employed. Regarding education status, 15% had
primary studies, 28% secondary studies, 19% technical stud-
ies, and 37% university studies. Most of the patients (70%)
underwent screening twice a week, 27.7% once a week, and
2.5% less than once a week.
The main functions attributed to urine screening by
patients and their frequencies can be seen in Table 1. Most of
the patients (82%) reported abstinence to be their therapeutic
objective. Only a small minority (14%) reported drinking
reduction as their aim. Half of the sample reported the
decision of undergoing regular urine screening was their
own, whereas 40% attributed it to their therapist and 4% to
a legal requirement. Almost half of the sample (44.3%)
believed people undergoing regular urine screening cheat
or try to cheat, whereas only 22% of the sample reported
having drunk small quantities of alcohol that have gone
undetected in the screening.
Regarding the adapted DAI-10 questionnaire, the mean
score was 7.2 (SD¼ 3.6). Internal consistency, measured with
Cronbach alpha, was 0.718, indicating fair reliability. Test-
retest reliability, measured from 20 subjects taking the ques-
tionnaire 2 to 4 weeks apart, revealed an intraclass correlation
coefficient of 0.932 (95% confidence interval [CI] 0.828–
0.973), indicating excellent test-retest reliability. The question
about the overall perceived value of urine screening showed a
mean of 8.46 (SD¼ 1.96). The correlation between this and
the DAI-10 score, as a mean to investigate concurrent validity,
was r¼ 0.254, with P¼ 0.009. No significant differences
were observed in these 2 measures between twice-per-week
attendants and less frequent attendants. Univariate corre-
lations did not show any significant difference in DAI-10
scores for any of the variables evaluated. Similarly, the
regression model revealed no significant predictor of DAI-
10 scores.
Regarding technical aspects of urine screening, the
majority of patients (78%) believed alcohol was the substance
detected in urine, whereas 11% thought it was other sub-
products of alcohol. Also, a majority (69%) believed a single
drink was enough to get a positive urine screening, 22%
believed 2 drinks were needed, 5% reported 3 drinks, and
4% reported 4 or more drinks. Regarding the detection
window of urine screening, findings are displayed in Figure 2.
DISCUSSION
In this study, we aimed at investigating the beliefs and
attitudes that patients have towards RAUS. Globally, we
believe the results suggest that alcohol patients perceive
routine urine screening as a highly valuable part of their
treatment.
The adapted version of the DAI-10 scored high among
our sample. Importantly, its internal reliability, with a Cron-
bach alpha of 0.718, was fair. Also, its correlation with a
single Likert-type question about the global perceived value
that patients give to regular urine screening, despite being
J Addict Med  Volume 00, Number 00, Month/Month 2017 Alcohol Screening: Patients’ Attitudes and Knowledge
 2017 American Society of Addiction Medicine 3
Copyright © 2017 American Society of Addiction Medicine. Unauthorized reproduction of this article is prohibited.
CE: M.S.; JAM-D-16-00138; Total nos of Pages: 8;
JAM-D-16-00138
mild in intensity, was clearly significant. It all leads to the
tentative conclusion that the results of the adapted DAI-10
questionnaire could be considered reasonably valid. Interest-
ingly, the high perceived value and positive attitude is in sharp
contrast with the lack of evidence regarding the efficacy of
regular urine drug screening (Dupouy et al., 2014). Whereas
the lack of evidence should not be interpreted as evidence of
no efficacy, if we take into account the previous results of a
We would like to thank you for your time in answering this completely
anonymous questionnaire about alcohol urine screening. We hope we will be
able to improve our services due to your participation.
- The decision of undertaking regular alcohol urine screening was taken by:
me  my therapist a court or a judge others (specify):
-My therapeutic goal is:
not to drink at all to reduce/control my drinking other (specify):
-To me, the main function of regular alcohol urine screening is (please select as many
as you wish):
to accomplish my objectives regarding alcohol
to prevent relapse
to demonstrate to professionals that I do not drink
to demonstrate to my family that I do not drink
to have a closer contact with professionals/to feel better cared for
to remind myself that I am in treatment because of alcohol
to comply with a court requirement
others (specify):
-Please select what is the overall value you give to regular urine screening (0 being
the lowest, 10 being the highest).
0 - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10
-I believe that, frequently, patients undergoing regular alcohol urine screening cheat
or try to cheat. true   false
-Sometimes I have drunk small amounts of alcohol and it has not been detected in the
urine screening. true false
-Please indicate if the following statements in your case are true (mark T) or false
(mark F):
1. For me, the good things about regular alcohol urine screening outweigh the bad T / F
2. I feel strange undergoing regular alcohol urine screening T / F
3. I undergo regular alcohol urine screening the days I decide, not the days I am
supposed to T/ F
FIGURE 1. Questionnaire for the evaluation of patients’ attitudes and knowledge towards regular alcohol urine screening.
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study conducted in the same population, in which self-reports
and routine ethanol screening performed clearly poor in
detecting alcohol use (Barrio et al., 2016), one is compelled
to think that there must be other reasons, apart from alcohol
use detection, why patients keep attending the urine screening
program.
Looking at patients’ responses, the majority stated that
preventing relapse and accomplishing their therapeutic goals
4. Undergoing regular alcohol urine screening makes me feel more safe and confident
T/F
5. Undergoing regular alcohol urine screening makes me feel tired and sluggish T / F
6. I only undergo alcohol urine screening when I have used alcohol T / F
7. I find it normal to undergo regular alcohol urine screening T / F
8. It is unnatural for me to undergo regular alcohol urine screening T / F
9. Undergoing regular alcohol urine screening allows me to think and act more clearly
T/ F
10.  Undergoing regular alcohol urine screening helps me not to get worse T / F
-What do you think is looked for or tried to detect in the urine when undergoing
alcohol use screening?
alcohol     some byproduct of alcohol breakdown I don’t know
-What would you say is the minimum amount of alcohol units that need to be ingested
in order to have a positive urine screening? (one alcohol unit is equivalent to one
beer, one glass of wine, one small shot of spirits or half long shot of spirits)
1               2        3 4 more than 4







longer than 72 h
-Your age:   years
-Your sex:  Male Female
-Are you employed? no yes
-Your level of instruction is:
primary studies secondary studies technical studies university
-How long have you been undergoing regular alcohol urine screening? __________
-You undergo regular alcohol urine screening:
twice or more a week once a week less than once a week
FIGURE 1. (Continued).
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regarding alcohol were the main functions of regular urine
screening. Notwithstanding, a high proportion of patients did
also report that having a closer contact with professionals,
feeling better cared for, and reminding themselves that they
were in treatment were also relevant functions of screening.
Taken together with the positive DAI-10 scores, we believe
these results point out to a human relational factor of notable
importance in the dynamics of regular urine screening.
Indeed, it should not be surprising, because it has long been
noted that the therapeutic relationship between patients and
professionals is of over-riding importance in the field of
alcoholism (Ritter et al., 2002; Ilgen et al., 2006). Although
to the best of our knowledge, there are no similar previous
studies regarding urine screening, a previous survey about
preferences of users in addiction services revealed that
patients clearly preferred help that involved human contact
compared with computerized help or self-help, irrespective of
personalized help being dispensed by professional or lay
providers (Tucker et al., 2009). Similarly, a recent study about
the needs of addiction patients in primary care highlighted the
importance of feeling cared for as a major characteristic for a
successful therapeutic relationship with their primary care
provider (Press et al., 2016). It should be taken into account
that in our study, patients were always received by the same
professional, a fact that might have facilitated an ongoing,
positive therapeutic interaction that might help explain our
results.
Regarding patients’ technical knowledge, as it could
have been expected, only a minority thought it was a break-
down product of ethanol that was detected in urine, suggesting
that ethylglucuronide and other subproducts of ethanol such
as ethylsulphate or phosphatidylethanol are big unknowns to
alcohol patients. What remains more interesting, however, are
the detection windows reported by patients. Although findings
are mixed, taken together, more than 75% of patients believe
alcohol use cannot be detected beyond 48 hours after con-
sumption. This might partly explain the high discrepancies
that studies comparing ethanol with ethylglucuronide have
consistently shown (Skipper et al., 2004; Wojcik and Haw-
thorne, 2007; Böttcher et al., 2008; Dahl et al., 2011; Jatlow
et al., 2014; Barrio et al., 2016), since ethylglucuronide might
be a reasonably valid metabolite to detect alcohol use beyond
48 hours of last alcohol consumption (Helander et al., 2009).
In trying to find other reasons explaining these consistently
reported discrepancies, it should be noted that more than 1 in 5
patients admitted to have drunk small quantities of alcohol
that have gone undetected by routine urinary ethanol detec-
tion, a proportion that could be even higher, since almost half
of the patients believed others might try to cheat while
undergoing urine screening. Taken together, all these data
suggest that, although patients do not have a fully accurate
knowledge of ethanol pharmacokinetics, they do have some
notions that could allow them to self-regulate their drinking to
avoid positive urine screenings. Be it because they do not
know about ethylglucuronide pharmacokinetics or because its
detection window expands beyond their self-regulatory
capacity, what becomes clear is that when urine screening
is performed with ethylglucuronide, the number of positive
screens dramatically increases. What remains to be investi-
gated is whether once patients become aware of ethylglucur-
onide kinetics, they will somehow regulate their drinking
again so as to reduce the number of positive urine samples.
A key issue in interpreting all studies using question-
naires is social desirability (Van De Mortel and Van De
Mortel, 2008). In fact, addiction is especially prone to such
bias (Davis et al., 2010; Zemore, 2012). Although question-
naires were completely anonymous, it cannot be totally ruled
out. In this sense, it is interesting to note the high proportion of
respondents that reported ‘‘showing professionals or their
family that they do not drink’’ as a main function of screening.
It suggests regular urine screening plays an important role in
patients’ interaction with both professionals and their social
network.
Other relevant limitations should also be taken into
account when interpreting our findings. First, we developed
a new questionnaire. Although it was based on an extensively
validated one such as the DAI-10, it must be acknowledged
that our study was not focused on questionnaire validation;
therefore, more measures could have been obtained to better
validate it. That being said, internal reliability and concurrent
validity were fair. It would have been interesting to correlate
the DAI-10 scores with adherence to urine screening by
assessing the rate of prescribed versus attended appointments.
However, we preferred to keep the questionnaires anonymous
to increase response validity. Another important limitation




To accomplish my therapeutic objectives
regarding alcohol
75
To prevent relapse 53.1
To show to professionals that I do not drink 39.8
To show to my family that I do not drink 35.9
To have closer contact with professionals/to
feel better cared of
39.8
To remind myself that I am in treatment
because of alcohol
42.2
To comply with a legal requirement 0.8
Others 0.8
FIGURE 2. Patients’ beliefs about detection windows for
alcohol urine screening.
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stems from the fact that all patients belonged to a single
outpatient center, a fact that might diminish external validity.
In this sense, for example, only a minority of patients under-
went urine screening due to legal requirements. It would be
reasonable to expect different results in settings where this
proportion is higher. It is also important to mention that the
nature of this study was mainly descriptive. However, we tried
to find some predictors of patients’ attitudes towards RAUS,
but found no significant predictors, a fact that could partly be
due to insufficient statistical power. Finally, a few question-
naires were not fully completed and therefore we had a minor
proportion of missing data.
CONCLUSIONS
We believe the results obtained in this study suggest
regular urine screening plays a significant role in abstinence-
oriented treatments. The lack of evidence regarding its effi-
cacy contrasts with the highly perceived value and attitudes
that patients display towards it. It looks like apart from the
more traditional therapeutic and relapse prevention function,
other more patient-centered or humanistic functions such as a
closer contact with professionals are also relevant. Also,
social desirability and impression management seem to be
key ingredients for a relevant portion of patients attending the
screening program. In consonance with the complexity of
addiction, this study also suggests that some patients try to
self-regulate their drinking to avoid positive urine screenings.
Further research should elucidate what the consequences are
of widely and routinely implementing more sensitive alcohol
biomarkers such as ethylglucuronide.
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The present thesis expands the current knowledge about the clinical implications of routinely 
screening alcohol dependent outpatients with urine ethyl glucuronide and thus adds extra value to 
this technique as a management strategy for alcohol dependent outpatients. 
Study 1 clearly signals that the increased detection capacity of recent drinking shown in 
previous experimental designs and small sample size studies is fully transferable to “real world” and 
“real practice settings”. It also demonstrates that urine ethyl glucuronide displays an overriding 
superior detection performance of recent drinking when compared to self-reports and clinician 
judgment. 
Study 2 provides new and useful information about the differential predictive capacity of 
positive and negative urine ethyl glucuronide regarding relapse and hospitalization risk in the 
following year, thus increasing the value and significance of routine urine screening in the 
management of alcohol dependence, both when a negative and a positive result is obtained. As 
shown by the results of the study, an EtG positive patient should raise clinicians’ awareness 
immediately, while an EtG negative patient could reassure clinicians of a favorable evolution, at least 
in the following months. Study 2 also suggests that ethyl glucuronide might have economical 
predictive implications as positive patients incur in more treatment expenses. All in all, Study 2 
opens the possibility of improved relapse prevention for alcohol dependent outpatients, suggesting 
relapse could be much earlier detected and therefore also earlier addressed.  
Finally, Study 3 provides insight into patients’ perspectives and technical knowledge 
regarding urine screening, demonstrating that a majority of patients highly value frequent urine 
testing as part of their alcohol treatment. Important reasons supporting this appreciation are relapse 
prevention, a closer contact with professionals and impression management. Study 3 also shows 
that patients have a low level of knowledge about ethyl glucuronide kinetics, a fact that could partly 




Ethyl glucuronide in routine, real clinical conditions 
 
Ethyl glucuronide signaling of alcohol use has been known for several years. The first 
demonstration of ethanol conjugation with glucuronic acid was seen in rabbits back in 1953 (87). It 
was not, however, until late 90s that ethyl glucuronide started to emerge in the field of alcohol 
research in humans (88–90). All studies conducted onwards have consistently shown that urine 
ethyl glucuronide behaves radically different from ethanol, especially when it comes to its wider 
detection window after alcohol ingestion. This means that ethyl glucuronide has persistently 
detected a higher number of positive samples when compared to ethanol. And the difference has 
been consistently high.  
While experimental assessments are clearly indispensable, they suffer from various 
caveats, such as assessment reactivity, Hawthorne’s effect, or even social desirability, all well 
known biases to scientific research (48,91). Therefore, what lacked to the existing literature (mostly 
based on experimental or highly controlled designs), was the confirmation that this different 
detection performance was to be sustained in routine, clinical settings under real circumstances.  
Study 1 provides data that suggest this is indeed the case. We found a large discrepancy 
between ethanol and ethyl glucuronide, one yielding only 1,5% of positive samples, the other 22,2%. 
These results are in line with previous studies. For example, Mutschler et al. (92) found in a group of 
51 outpatients under supervised disulfiram a 59% discrepancy between EtG and breath alcohol 
testing. Similarly, Junhagams et al. (66) found a 28% discrepancy between EtG and self reports  in 
139 outpatients. The studies by  Wurst et al.(76) and Skipper et al. (93), in which EtG was compared 
to urinary alcohol, reported a discrepancy of 9% and 7%, respectively.  
Beyond numbers, the relevant point of Study 1 is that the large discrepancy found between 
ethanol and ethyl glucuronide could be seen as the two metabolites depicting totally different 
realities. If we were to rely only on urinary ethanol, it would look like the great majority of our 
outpatients do exceedingly well in an abstinence oriented program, with less than 5% of patients 
drinking alcohol. On the other hand, if we consider the data provided by EtG assessment, the picture 
is radically different. We no longer have a big population of alcohol patients who cope with their 
alcohol problems in a way that they are able to maintain abstinence. We indeed have almost a 40% 
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of patients who are not fully abstinent. And, importantly, were it not for EtG, we would not be aware 
of this huge proportion.  
Self reports were, in Study 1, even less reliable than ethanol. It is indeed well known that 
self-reports tend to underestimate patients’ consumption rates (94–97). The rate of positives 
suspected by the nurse was halfway between those of EtG and urinary ethanol, suggesting up to 
10,5% of urine samples came from not abstinent patients. In fact, previous studies suggest clinicians 
are ill-equipped when it comes to assess substance intake in their patients (98).  
All in all, Study 1 suggests that ethyl glucuronide is an indispensable, and probably one of 
the best tools in order to assess the reality of alcohol dependent outpatients when it comes to 
determine their drinking status. It follows that in clinical settings where it is not implemented, and 
where routine urinary or breath ethanol screening is conducted aiming at relapse prevention, such 
performance might be rather poor, even if incorporating professionals’ expertise and judgment into 
the equation. Given the high impact alcohol use imposes on individuals and societies, it seems 
reasonable to believe that an effort to expand the implementation of urine ethyl glucuronide is 
warranted.  
As a conclusion, the data displayed by this and other studies clearly suggest that a wide 
implementation of EtG in real settings would yield relevant improvements in the monitoring of 
abstinence in outpatient populations, therefore offering a better relapse prevention. 
 
Ethyl glucuronide prediction of clinical evolution 
 
Following participants of Study 1, Study 2 evaluated one-year clinical correlates of positive 
baseline EtG urine screening, as compared to a negative baseline result. Both patients and clinicians 
were unaware of baseline EtG results. Since we could not incorporate EtG testing as our routine 
biomarker due to budget and time constraints in the following year, the ongoing urine screenings were 
performed with ethanol. This in fact allowed the performance of Study 2, where the implications of a 
single EtG testing could be evaluated.  
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The data obtained during the follow-up suggest that patients testing positive in EtG will have a 
different clinical evolution in the following year, with a significant increase in relapses, hospitalizations 
and treatment expenses. Given that both patients and clinicians were unaware of EtG status at 
baseline, one pressing question emerges: could some of this differences have been avoided, was this 
information made available to them? Although such a question cannot be directly answered by Study 
2, and needs for prospective, randomized investigations, we believe some clues can be drawn from 
its data.  
Although the need for hospitalization for the whole sample was rather low, with only 10 
patients (6,6% of the total sample) requiring it, the differences between groups were both significant 
and large, with only one patient in the EtG negative arm being hospitalized in the following year. 
Taking a stepped care approach, hospitalization could be considered as one of the final steps in 
dealing with a relapse, which might have been initiated much before in the form of lapses (99,100). 
This might be a crucial point in time where the use of sensible alcohol biomarkers such as EtG could 
help to identify the beginning of the relapse, and so to earlier address it, with the potential impact of 
avoiding the need for hospitalization and also of reducing treatment expenses. 
Though at first glance suggesting that patients who test positive for EtG will relapse at a 
higher rate than those who don’t could seem tautological, this fact deserves further elaboration. First, 
one should notice that relapse, though widely used as a concept, lacks firm and conclusive criteria 
(101), a fact that could explain that being EtG positive does not immediately imply a relapse. In fact, a 
minority of patients tested positive for EtG and were clinically deemed as non-relapsed during the 
following year. That being said, our data robustly show that an EtG positive result dramatically 
increases the risk of having a clinical correlate in the following year, as shown by the hazard ratio 
obtained in the survival analysis. In other words, patients testing positive for EtG will, with very high 
probabilities, ultimately have clinical symptoms of relapse. Therefore, an EtG positive screening could 
be considered as an early relapse sign. But also, looked the other way around, it looks like having an 
EtG negative screening has a strong negative predictive value, that is, it should reassure clinicians of 
patients’ favorable evolution, at least in alcohol related outcomes.  
Results of study 2 are in line with previous, similar studies. For example, Junghans et al. (66), 
found out that positive EtG urine screening early after discharge significantly increased the rate of 
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subsequent relapse in recently discharged alcohol dependent patients. Similarly, Dahl et al. (102) 
found EtG to be a useful and reliable ongoing monitoring tool in alcohol treatment studies, specially 
suggesting that an initial EtG negative sample is useful to confirm self-reports.   
Treatment expenses were clearly different between groups, driven both by the different 
number of days of hospitalization in both cohorts as well as an increased number of visits in those 
EtG positive. In fact, it has already been shown that patients actively drinking incur in greater costs 
(103–105). All these data suggest that the implementation of EtG could also have an economic impact 
in the treatment of alcohol dependence.  
Regarding the capacity of predicting the risk of being lost to follow-up, EtG showed significant 
results in the univariate analysis, which seemed to disappear once age was included in the 
multivariate model. In fact, previous literature already pointed out at older age as a predictor of 
treatment retention (106,107). That being said, prior literature also consistently shows that patients 
actively using alcohol or drugs are at a greater risk of becoming non-treatment adherent 
(106,108,109). Also, previous studies with EtG (66) have found that testing EtG positive increases the 
risk of being lost to follow-up. Therefore, it would not be unwise to consider EtG as a potentially useful 
tool in predicting the risk of treatment abandonment.  
Taken together, we believe that the data gathered by study 2 has important implications for 
real practice: namely, the implementation of ethyl glucuronide in routine urine screening could 
improve clinicians’ capacity to detect early signs of relapse, and therefore it would also allow them to 
early address it, increasing the efficiency of the process. Also, it looks like both the positive and 
negative predictive value of EtG could allow for a better targeting of those patients that are in need of 
a more urgent, intense intervention. Given the high rate of relapse displayed by EtG positive patients, 
it seems that a positive testing for EtG should raise clinicians’ awareness immediately, while an EtG 
negative result could reassure them of a favorable evolution, at least in the following months.  
While there is a solid body of evidence assessing the predictive capacity of other variables 
such as illness severity (107), craving (111), DSM-IV criteria (112), or other psychological constructs 
such as persistence and self-efficacy (113) when trying to determine the risk of relapse, there is no 
such literature related to the predictive capacity of urine screenings. And the same happens when 
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analyzing the risk of hospitalization (114–116). In fact, in study 2, we found EtG to be the most 
accurate, precise predictor, even when controlling for other variables such as age, sex, addictive 
comorbidities or length of urine testing, and also clearly better than clinician judgment. Therefore, EtG 
status should not be seen as a substitute of other important variables, but it clearly increases the 
global assessment and prediction capacity of clinicians treating alcohol dependent outpatients.  
All in all, we believe Study 2 increases the available evidence supporting the usefulness and 
clinical impact of regular urine screening with sensible biomarkers in alcohol treatments. Though no 
efficacy data could be directly inferred from our data, it looks like a wide implementation such sensible 
alcohol biomarkers could help to improve the prediction capacity of clinicians, especially in abstinence 
oriented settings. Further prospective studies will have to examine whether this increased prediction 
capacity can be translated into a greater treatment efficacy, probably due to a better prevention.  
 
Patients’ Perspectives  
 
The appearance of new alcohol biomarkers with overriding superior sensibilities in the 
detection of drinking has made clear that routine urine screening has been far from satisfactory when 
it comes to abstinence monitoring.  The huge discrepancy found in Study 1 and all other studies 
comparing new biomarkers with traditional ones lead to a pressing question: what is the real purpose 
of regular urine screening? Is it about regular control, relapse prevention and contingency 
management? Or is it about education, habit changing routines and continuous support? Or is it both? 
That was partly what we tried to answer in Study 3, aimed at investigating the beliefs and attitudes 
patients have towards regular alcohol urine screening.  
Globally, the results of Study 3 show that alcohol patients perceive routine urine screening as 
a highly valuable part of their treatment. The adapted version of the DAI-10 scored high among our 
sample. Importantly, its internal reliability, with a Cronbach’s alpha of 0,718, was fair. Also, its 
correlation with a single Likert-type question about the global perceived value patients give to regular 
urine screening, despite being mild in intensity, was clearly significant. It all leads to the tentative 
conclusion that the results of the adapted DAI-10 questionnaire could be considered reasonably valid.  
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Interestingly, the high perceived value and positive attitude is in sharp contrast with the lack of 
evidence regarding the efficacy of regular urine drug screening. While the lack of evidence should not 
be interpreted as evidence of no efficacy, if we take into account the results of Study 1, where self-
reports and routine ethanol screening performed clearly poor in detecting alcohol use, one is 
compelled to think that there must be other reasons, besides alcohol use detection, why patients keep 
attending the urine screening program.  
Looking at patients’ responses, the majority stated that preventing relapse and accomplishing 
their therapeutic goals regarding alcohol were the main functions attributed to regular urine screening. 
Notwithstanding, a high proportion of patients did also report that having a closer contact with 
professionals, feeling better cared for and reminding themselves that they were in treatment were also 
main functions of screening. Taken together with the positive DAI-10 scores, we believe these results 
point out to a human relational factor of notable importance in the dynamics of regular urine 
screening. Indeed, it should not be surprising, since it has long been noted that the therapeutic 
relationship between patients and professionals is of overriding importance in the field of alcohol 
dependence (117,118). While to the best of our knowledge there are no similar previous studies 
regarding urine screening, a previous survey about preferences of users in addiction services 
revealed that patients clearly preferred help that involved human contact compared to computerized 
help or self-help, irrespective of personalized help being dispensed by professional or lay providers 
(119). Similarly, a recent study about addiction patients’ needs in primary care did also highlight the 
importance of feeling cared for as a major characteristic for a successful therapeutic relationship with 
their primary care provider (120). It should be taken into account that in our study, patients were 
always received by the same professional, a fact that might have facilitated an ongoing, positive 
therapeutic interaction that might help explain our results.  
Regarding patients’ technical knowledge, as it could have been expected, only a minority 
thought it was a breakdown product of ethanol that was detected in urine, suggesting that 
ethylglucuronide and other subproducts of ethanol such as ethylsulphate or posphatidylethanol are 
big unknowns to alcohol patients. What remains more interesting, however, are the detection windows 
reported by patients. While findings are mixed, taken together, more than 75% of patients believe 
alcohol use cannot be detected beyond 48 h after consumption. This might partly explain the high 
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discrepancies that studies comparing ethanol with ethylglucuronide have consistently shown 
(61,63,65,76,121), since ethylglucuronide might be a reasonably valid metabolite to detect alcohol use 
beyond 48 hours of last alcohol consumption (54). In trying to find other reasons explaining these 
consistently reported discrepancies, it should be noted that more than one in five patients in Study 3 
admitted to have drunk small quantities of alcohol that had gone undetected by routine urinary ethanol 
detection, a proportion that could be even higher, since almost half of the patients believed others 
might try to cheat while undergoing urine screening. Taken together, all these data suggest that 
although patients have not a fully accurate knowledge of ethanol pharmacokinetics, they do have 
some notions that could allow them to self-regulate their drinking in order to avoid positive urine 
screenings. Be it because they do not know about ethylglucuronide pharmacokinetics or because its 
detection window expands beyond their self-regulatory capacity, what becomes clear is that when 
urine screening is performed with ethylglucuronide the number of positive screens dramatically 
increases. What remains to be investigated is whether once patients become aware of 
ethylglucuronide kinetics, they will somehow regulate their drinking again so as to reduce the number 
of positive urine samples. 
We believe the results obtained in Study 3 suggest that regular urine screening plays a 
significant role in abstinence oriented treatments. The lack of evidence regarding its efficacy contrasts 
with the highly perceived value and attitudes that patients display towards it. It looks like besides the 
more traditional therapeutic and relapse prevention function, other more patient-centered or 
humanistic functions such as a closer contact with professionals are also relevant. Social desirability 
and impression management seem also to be key ingredients for a relevant portion of patients 
attending the screening program. In consonance with the complexity of addiction, Study 3 also 














Several limitations must be taken into account when interpreting the findings of the present 
thesis. Regarding Study 1, and related to EtG measurement, it is important to note that EtG false 
positives are known to occur after the ingestion of mouthwashes or the use of alcohol-containing hand 
sanitizers. However, this might account only for a residual number of positives. Moreover, with a cut-
off of 500 ng/ml, the specificity of EtG remains quite high (122). In fact, previous studies suggests that 
a cut-off of 500 mg/nl reliably prevents these false positives from occurring (123–125). Also, 
EtG/creatinine ratios and EtG-LC-MS/MS confirmation tests were not conducted. Nonetheless, recent 
studies (61,64,126) suggest that this is not necessary. Also, despite being an observational study with 
an expected high external validity, the results belong to a single center, a fact that might limit the 
generalization of the results.  
Turning to Study 2, it should be noted that data were gathered at the end of follow-up, which 
means that variables were collected retrospectively. Taking into account that we also collected the 
hospitalization rate of patients, it should be considered that there exists the possibility of patients 
being hospitalized in other centers, which could have biased our data. However, it would be 
reasonable to consider that in both groups more hospitalizations would have been seen, and probably 
even more in the EtG positive patients. Therefore this bias would result in an infraestimation of EtG 
prediction capacity, which, as it has been shown, turned out to be already significant. Related to this, 
is the fact that more EtG positive patients were lost to follow-up. While survival analysis specifically 
addresses this data, when analyzing days of hospitalization and relapse risk, they had to be 
considered as missing data. However, as previously mentioned, treatment abandonment has been 
associated with increased relapse risk, therefore, it is probable that this missing data turned out into 
an infraestimation of EtG prediction capacity regarding relapse risk and hospitalization risk. Also 
relevant to mention is the fact that relapse as an outcome was operationalized according to different 
criteria, a fact that could limit the validity of our results. That being said, composite endpoints are now 
frequently used and reasonably valid if well and appropriately designed (127,128).  Finally, it is 
important to note that psychiatric comorbidities, a frequent phenomenon in alcohol dependent patients 
(129,130) were not systematically recorded in this study, and therefore, their contribution to the results 
obtained could not be evaluated.  
73 
 
Finally, in Study 3, a key issue, as in all studies using questionnaires, is social desirability 
(131). In fact, addiction is especially prone to such bias (132,133). Although questionnaires were 
completely anonymous, it cannot be totally ruled out. Also relevant is the fact that we developed a 
new questionnaire. Although it was based on an extensively validated one such as the DAI-10, it must 
be acknowledged that our study was not focused on questionnaire validation, therefore more 
measures could have been obtained in order to better validate it. However, internal reliability and 
concurrent validity were fair. Another important limitation stems from the fact that all patients belonged 
to a single outpatient center, a fact that might diminish external validity. In this sense, for example, 
only a minority of patients underwent urine screening because of legal requirements. It would be 
reasonable to expect different results in settings where this proportion is higher.  
 
Connecting the dots: what is this thesis showing us? 
 
We believe that with the evidence provided by this thesis, it is reasonable to argue that 
regular alcohol urine screening with biomarkers such as EtG is a relevant component in the 
management of alcohol dependent outpatients, and that it seems to have an effect on patients’ clinical 
evolution. It is also reasonable to argue that this effect stems from two separate mechanisms: one 
would be EtG’s excellent internal validity and extended detection times as well as high predictive 
values. The second one would be independent of the biomarker characteristics, and would be related 
to the opportunity that regular alcohol urine screening offers to both patients and professionals for 
therapeutic alliance building and an improved, better perceived, patient care.   
This, in fact, reminds us that medicine is not all about technique, and that scientific progress 
should always furnish the framework for a stronger humanistic, value-based medicine (134). Though 
EtG is merely a molecule, we believe that it can indeed bring both scientific and humanistic progress. 
Clearly, EtG will help clinicians to better assess and comprehend patients’ reality, opening new 
possibilities for a more accurate and compassionate care. Where clinicians were blind before, they will 
now have the opportunity to discuss with patients what their difficulties are in achieving and 
maintaining abstinence. We also expect that the improved, more accurate feedback that patients will 
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get from EtG will, in the end, help them through the arduous, but so many times enlightening, process 
of recovery.  
 
Future directions and challenges 
 
Patients’ assessment and correct evaluation are essential in all medical branches and 
diseases. When it comes to addiction patients, it is key to accurately know whether patients are 
abstinent or not. Though probably not a single tool fits all patients and settings, it looks like good 
biomarkers, with high sensitivity and specificity, and with extended detection window, are essential 
components in abstinence oriented treatments.   
In this sense, the emergence of new alcohol biomarkers has clearly opened new and 
promising possibilities, taking the field closer to a better and more accurate appreciation of reality. 
However, both evidence based medicine and patient complexity and heterogeneity require that all 
new treatments, assessment tools or whatever elements, undergo a rigorous research process aimed 
at demonstrating their efficacy. We hope this thesis has added relevant evidence into the field. 
However, we are aware that more efforts are needed in this direction.  
Throughout this thesis we have mentioned several times the potential relapse prevention 
improvement that EtG might yield if widely implemented in outpatient settings. However, to date, there 
is no study assessing the performance of EtG in relapse prevention in a randomized design. In fact, 
randomized studies of diagnostic techniques have been largely neglected in many health areas (135–
137). Comparing sensitivity and specificity of diagnostic techniques in a transversal design, as it is 
usually the case when developing new diagnostic strategies, precludes drawing firm conclusions 
about their clinical effectiveness. Just as drug-therapies and behavioral interventions ultimately rely on 
randomized trials to establish their clinical significance, so should diagnostic techniques.  
The lack of randomization when assessing the effectiveness of a diagnostic test used in 
alcohol screening is especially worrisome for at least two reasons. First, it is reasonable to believe 
that the screening workup of alcohol use disorders has a therapeutic effect via feedback to the 
patient, thus it is of crucial relevance that the performance of the screening tools is assessed using a 
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randomized design. Second, unlike in other diseases where a positive diagnostic test is expected to 
be followed by a highly standardized intervention , there is no such standardization in the addiction 
field, and the gap between a positive screening and the related clinical consequences should be 
elucidated.  
Thus, in order to fully and firmly discern the ultimate contribution of EtG to alcohol use 
disorders’ management, its well established superior diagnostic performance in urine screening is not 
enough. That is the reason why we are currently conducting a randomized study where 160 patients 
have been randomized to 24 weeks of ongoing urine screening with ethanol or ethyl glucuronide, in 
order to assess the differential impact EtG could have in alcohol related outcomes, with special 
emphasis on relapse prevention.  
Finally, it is important to note that despite EtG being probably the most studied new biomarker 
of alcohol use, many others might follow in the coming years. We believe special attention is deserved 
by posphatidylethanol, especially now that its measurement in dried blood spots is available (138–
140), and that specific antibodies have been produced (141), facts that could accelerate its routine, 
seriated implementation.  
In this sense, the expanding science of proteomics displays also promising features for 
alcohol biomarkers (142–144). That being said, it is important to understand that the development of a 
new biomarker is a long, arduous journey, departing from discovery and arriving at clinical validation 
and implementation. Thus, we believe it is important to mention that this thesis has served as the final 
destination for urine ethyl glucuronide in our site, where it has now been implemented as the routine 


























































1. Urine ethyl glucuronide detection capacity of recent drinking is clearly superior to that of 
ethanol, self-report or clinician judgment in routine clinical settings, under real circumstances. 
 
2. Urine ethyl glucuronide has a relevant prediction capacity regarding relapse risk, with patients 
screening positive having a higher rate of clinical significant relapse in the following 12 
months. 
 
3. Urine ethyl glucuronide has a relevant prediction capacity of need of hospitalization, with 
patients screening positive spending more days hospitalized during the following 12 months.  
 
4. Urine ethyl glucuronide has a relevant prediction capacity regarding treatment expenses, with 
patients screening positive incurring in higher costs. 
 
5. Patients have a low level of knowledge regarding urine ethyl glucuronide as well as other 
concepts related to urine screening, including the detection window of EtG. 
 
6. Patients highly value regular alcohol urine screening as part of their treatment. The main 
functions they attribute to it are improved relapse prevention, a closer contact with 

















































Reemplazo de etanol por etilglucurónido  en el 
cribado rutinario de pacientes ambulatorios 




El consumo de alcohol es una de las tres primeras causas de carga de enfermedad a nivel 
mundial (1). En Estados Unidos representa la tercera causa prevenible de muerte (4), mientras que  
Europa, con más de 15 millones de individuos afectos por un trastorno por uso de alcohol, posee el 
mayor número de muertes atribuibles al alcohol (5). Se añade además el problema del gran número 
de pacientes que no reciben tratamiento (6–8), todo ello implicando grandes repercusiones tanto a 
nivel individual como social (9), convirtiendo al alcohol en una prioridad de salud pública.  
La forma más severa de trastorno por uso de alcohol, la dependencia al alcohol (10), es una 
enfermedad crónica recurrente, donde las recaídas son un fenómeno frecuente (12–14). Las 
consecuencias que supone para los pacientes afectos son muchas y diversas, tanto a nivel orgánico 
como psiquiátrico, incluyendo trastornos depresivos, ansiosos, accidentes, enfermedades 
gastrointestinales, cirrosis hepática, problemas sociales y legales, entre muchas otras más (18,19).  
El tratamiento más eficaz para los tratarnos por uso de alcohol es aquel que combina 
estrategias psicosociales y farmacológicas (24). Dentro de estas dos modalidades, existen múltiples 
opciones  que han demostrado ser eficaces en multitud de estudios previos, tales como la terapia 
cognitivo-conductual, la entrevista motivacional, el manejo de contingencias (25–32), la naltrexona, el 
acomprosat, el disfulfiram, el baclofeno o el topiramato (33–37).  
En relación al objetivo del tratamiento, aunque ha sido siempre un tema debatido y es bien 
sabido que la reducción de daños junto a la reducción de consumos es una estrategia válida y 
frecuente en el mundo de los trastornos adictivos (40–42), la abstinencia es en general el objetivo de 
elección para una gran mayoría de pacientes y profesionales, puesto que, conceptualizando la 
adicción como una incapacidad de control sobre una sustancia, es considerada la vía más eficiente y 
segura hacia la total recuperación, tanto a nivel médico como psicosocial (43,44).  
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Por tanto, la monitorización de la abstinencia es una tarea indispensable para los 
profesionales que tratan pacientes dependientes al alcohol. En este sentido, y para realizar dicha 
tarea, los profesionales cuentan con varios métodos. Cabe comentar primeramente el autoinforme de 
los pacientes, que si bien es un elemento importante (47), son conocidos también todos sus sesgos y 
su baja fiabilidad cuando se compara con métodos más sensibles (48). Los biomarcadores son otra 
herramienta que puede complementar y mejorar el uso de autoinformes, pudiendo además ser claves 
para la monitorización de la abstinencia (49). Los marcadores tradicionales obtenidos en sangre 
(volumen corpuscular medio, gamma-glutamil transferasa, transferrina deficiente en carbohidratos) 
son poco sensibles a la hora de detectar pequeños consumos, por lo que no son buenos candidatos 
para una correcta monitorización de la abstinencia (46-48). Lo mismo le sucede al etanol en orina, 
que sólo permanece positivo unas pocas horas tras el último consumo de alcohol (54). 
Afortunadamente durante la última década se han producido avances importantes en el 
campo de los biomarcadores del consumo de alcohol, siendo especialmente relevante el caso del 
etilglucurónido (EtG). Aunque sólo una pequeña parte del etanol ingerido se degrada mediante la 
conjugación con ácido glucurónico, esta molécula hidrosoluble puede permanecer detectable en orina 
hasta 72 horas después del último consumo de alcohol, por lo que hace posible una mayor ventana 
de detección del consumo de alcohol y posibilita una detección temprana de consumos y una mejor 
prevención de recaídas, al menos desde un punto de vista teórico.  
Hasta la fecha se han realizado diversos estudios sobre EtG. No obstante, muchos han sido 
realizados bajo paradigmas de consumo controlado para estudiar su farmacocinética,(60–63), otros 
han sido estudios imbuidos en otros ensayos clínicos experimentales, (61,64–67), y otros han sido 
estudios con pequeño tamaño muestral o realizados con pacientes hospitalizados (74–77). Es por 
todo esto que es necesario estudiar el rendimiento diagnostico del EtG bajo condiciones reales de 
elevada validez externa, un criterio que frecuentemente es marginado en los estudios experimentales 
y que supone importantes sesgos (64-69). Por todo esto, el Estudio 1 se realizó para comparar el 
rendimiento diagnostico del EtG con el del etanol, el juicio clínico y el autoinforme bajo condiciones 
reales de elevada validez externa, en un diseño transversal.  
Otro interrogante en el cribado de alcohol es cuán eficaz es dicha técnica en el tratamiento 
de los pacientes. En este sentido una revisión sistemática reciente señala que existen escasos datos 
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al respecto (78). De hecho, ningún estudio con anterioridad ha evaluado las implicaciones clínicas 
que supone un resultado EtG positivo en cuanto a riesgo de recaída, riesgo de hospitalización y 
costes de tratamiento. Esta es la pregunta que intentó resolver el Estudio 2, donde los pacientes del 
estudio 1 fueron evaluados durante los siguientes 12 meses mediante un análisis de supervivencia 
con el fin de investigar la evolución clínica diferencial entre los pacientes EtG positivo y EtG negativo  
Finalmente, teniendo en cuenta que hasta la fecha los datos sugieren que la detección del 
consumo de alcohol en pacientes ambulatorios dista de ser adecuada, parece razonable preguntarse 
si existen otras razones por las cuales los pacientes acuden regularmente al cribado de orina para 
monitorizar la abstinencia. Esto es lo que trató de evaluar el Estudio 3, donde a través de un 
cuestionario se evaluaron también los conocimientos técnicos de los pacientes respecto al cribado de 
alcohol.   
 
Objetivos e hipótesis 
 
El objetivo primordial de la presente tesis es ampliar el conocimiento existente sobre las 
implicaciones clínicas del cribado regular de alcohol en orina mediante métodos de alta sensibilidad y 
especificidad, como es el caso del EtG. Ello implica establecer su rendimiento en condiciones de 
rutina y elevada validez externa, así como investigar qué diferencias existen entre los pacientes 
positivos y negativos en los meses siguientes, en relación a riesgo de recaída, hospitalización y 
costes sanitarios. Finalmente es un objetivo también primordial conocer las actitudes y conocimientos 
de los pacientes en relación al cribado regular de alcohol. Estos objetivos se articulan en las 
siguientes hipótesis:  
 
1. El uso de etilglucurónido resultará en un mayor número de muestras positivas en relación al 
uso de etanol, juicio clínico y autoinformes, debido a su mayor ventana de detección y su 
mayor sensibilidad.  
2. Debido a que las recaídas se inician frecuentemente en forma de consumes encubiertos, el 
etilglucurónido identificará pacientes en fases iniciales de recaída, lo que supone que aquellos 
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pacientes EtG positivo presentarán en los siguientes meses mayor riesgo de recaída y 
hospitalización, así como un mayor gasto sanitario. 
3. Debido a su relativa novedad, es esperable que los pacientes tengan un bajo nivel de 
conocimiento sobre el EtG y su farmacocinética.  
4. Asumiendo que los pacientes tienen razones y expectativas diversas en relación al cribado 
rutinario de alcohol en orina, hipotetizamos que se obtendrán resultados mixtos en relación a 
sus actitudes respecto a dicha estrategia. Se espera que algunos pacientes la vean como una 
ayuda en su camino hacia la abstinencia, mientras que otros la experimenten como una 






El Estudio 1 consistió en una comparación transversal de todas las muestras de orina 
recogidas consecutivamente durante 14 días, analizándose todas para EtG, etanol, juicio clínico y 
autoinforme. El etilglucurónido fue analizado mediante un ensayo inmunoenzimático basado en un 
anticuerpo monoclonal  (DRI Ethyl Glucuronide Enzyme Immunoassay , DRI-EtG EIA, Thermo Fisher 
Scientific Diagnostics, Hemel Hempstead, UK). Otras variables recogidas fueron las comorbilidades 
adictivas, la antigüedad en el cribado de alcohol y los datos sociodemográficos básicos. Se comparó 
la tasa de positivos entre etanol y EtG, así como el rendimiento diagnóstico del juicio clínico 
considerando el EtG como patrón oro. Se realizó un análisis de regresión en busca de predictores de 
un resultado EtG positivo.  
El Estudio 2 analizó un año después la presencia de recaídas, hospitalizaciones y costes 
sanitarios en los participantes del Estudio 1. Dichas variables fueron recogidas de manera 
retrospectiva y se llevó a cabo un análisis de supervivencia (junto a una regresión de Cox), 
comparando los grupos según su fueron EtG positivo o EtG negativo en relación al riesgo de recaída. 
Se utilizaron modelos de regresión lineal para comparar entre grupos el número medio de días de 
hospitalización y los costes sanitarios en que incurrieron, con la finalidad de encontrar predictores 
significativos de las posibles diferencias existentes entre grupos.  También se comparó el número de 
pacientes que abandonaron tratamiento entre ambos grupos mediante análisis de regresión logística. 
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Todos los modelos fueron repetidos de nuevo sustituyendo el EtG por el juicio clínico, con el fin de 
comparar su poder predictivo.  
En el Estudio 3 se llevó a cabo de manera transversal, la realización de un cuestionario por 
parte de los pacientes ambulatorios dependientes al alcohol de la misma población que los estudios 
previos. Para evaluar sus actitudes se adaptó el Drug Attiude Inventory (DAI-10) al campo del cribado 
rutinario de alcohol, analizándose su consistencia interna, su fiabilidad test-retest y su validez 
concurrente. Para la evaluación de conocimientos se llevaron a cabo preguntas de respuesta 
múltiple. Se llevaron a cabo análisis de regresión lineal con la finalidad de encontrar predictores de 




En el Estudio 1 un total de 188 pacientes proporcionaron 613 muestras consecutivas de 
orina durante 14 días.  El etanol identificó 9 muestras como positivas, pertenecientes a 8 pacientes. 
El etilglucurónido identificó 136 muestras positivas, pertenecientes a 74 pacientes. Un 28,1% 
(172/613) de muestras fueron cribadas para otras drogas, principalmente cannabis (125 sobre 613 
muestras), resultando positivas un 9,6% de las mismas en el cómputo global de muestras (59/613).  
En el modelo de regresión logística, solo el juicio clínico y la presencia de medicación aversiva fueron 
predictores significativos del resultado de EtG. El juicio clínico de la enfermera encargada de recibir a 
los pacientes y sus muestras, clasificó un 89,7% de las muestras (550/613) pertenecientes a 178 
pacientes, como abstinentes. Juzgó un 7,8% (48/613) de las muestras, pertenecientes a 26 
pacientes, como no abstinentes, dudando en 15 muestras de 15 pacientes. Usando el EtG como 
patrón oro, se obtuvo un área bajo la curva de  0,592. 
En el Estudio 2 se incluyeron 152 pacientes para el análisis de supervivencia. Las curvas de 
Kaplan-Meier mostraron una clara diferencia entre sujetos EtG positivo y EtG negativo (Log-Rank test 
significativo; chi=58,382 df=1; p<0,001). El promedio de tiempo hasta la recaída fue de 163 días en 
los sujetos EtG positivo y de 329 días en los EtG negativo. La regresión de Cox estableció el EtG 
como el único predictor significativo de dicha diferencia (hazard ratio = 5,3; IC 95% de 3,1 a 9,1). Lo 
mismo sucedió en los análisis de regresión lineal en relación al número medio de días de 
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hospitalización y el coste medio del tratamiento durante los siguientes 12 meses, donde el EtG fue el 
único predictor significativo. En este sentido, los pacientes EtG positivo presentaron mayor número 
medio de días de hospitalización (6,04 frente a 0,28 días) y mayores costes sanitarios promedio 
(2167 € frente a 566 €). El único factor predictor de riesgo de abandonar tratamiento fue la edad, 
asociándose una mayor edad a un menor riesgo (OR= 0,94; IC95% de 0,88 a 0,98). Al sustituir el 
EtG por el juicio clínico, en ninguno de los modelos previamente explicados obtuvo esta variable la 
significación estadística.  
En el Estudio 3, se obtuvieron cuestionarios de 128 pacientes. Se observó una valoración 
muy positiva por parte de estos en relación al cribado rutinario de alcohol en orina, obteniéndose una 
puntuación media del cuestionario adaptado DAI-10 de 7,2 puntos (DE= 3,6). La alfa de Cronbach 
fue de 0,718. El coeficiente de correlación intraclase, utilizado para medir la fiabilidad test-retest fue 
de 0,932. La correlación entre la puntuación del cuestionario y la puntuación de una pregunta tipo 
Likert sobre cuánto valoran globalmente los pacientes el cribado rutinario de alcohol del 0 al 10 
obtuvo un coeficiente de correlación de 0,254, con una p de 0,009. A parte de la prevención de 
recaídas, otras funciones importantes reportadas por los pacientes fueron demostrar a la familia y los 
profesionales que no beben y tener un contacto más cercano con los profesionales. La mayoría de 
pacientes refirió creer que el consumo de alcohol no se puede detectar pasadas 48 horas desde la 




Etilglucurónido en condiciones rutinarias de alta validez externa  
 
El Estudio 1 sugiere que la elevada sensibilidad y especificidad del etilglucurónido para la 
detección de consumos recientes que se ha observado en estudios previos de tipo experimental, es 
claramente transferible a las condiciones clínicas rutinarias donde los pacientes dependientes del 
alcohol son monitorizados con el fin de preservar la abstinencia. Además, este estudio sugiere que si 
no fuera por la incorporación de un biomarcador de las características del EtG, nuestra percepción de 
la realidad sería claramente sesgada. Sin ir más lejos, si usamos los datos proporcionados por el 
etanol, parece que menos del 5% de nuestros pacientes no están abstinentes, mientras que si 
86 
 
utilizamos los datos que aporta el EtG, esta proporción asciende hasta casi el 40%. Los autoinformes 
fueron incluso menos fiables que el etanol. De hecho existe literatura previa señalando la tendencia 
de los autoinformes a infravalorar los consumos de los pacientes (94–97). El juicio clínico estimó que 
un 10,5% de las muestras pertenecían a pacientes no abstinentes. Este número está a medio camino 
entre el etanol y el etilglucurónido. De hecho, estudios previos sugieren que los profesionales no 
poseen una buena capacidad de detección de consumo de sustancias en sus pacientes (98).  
En su conjunto, el Estudio 1 sugiere que el EtG es una de las mejores herramientas que 
existen en la actualidad para determinar la abstinencia de los pacientes dependientes al alcohol. Esto 
sugiere que se debería tratar de implementar de la manera más extensiva posible en los diversos 
ámbitos clínicos donde esta monitorización es importante, puesto que de no hacerlo, se corre un 
elevado riesgo de interpretar la realidad de una manera altamente sesgada. El estudio sugiere 
también que el uso de etilglucurónido podría mejorar significativamente la prevención de recaídas, 
permitiendo su detección de forma más temprana y por tanto también permitiría un abordaje más 
temprano y eficiente.  
 
Etilglucurónido y predicción de la evolución clínica  
 
El hecho que tanto los pacientes como los profesionales no dispusieran de los resultados 
obtenidos en el Estudio 1, y que los controles posteriores se realizaron, como es habitual en nuestro 
centro, con etanol, permitió la evaluación longitudinal de los pacientes haciendo posible el estudio de 
la capacidad predictiva de un resultado positivo a EtG en relación a diversos parámetros clínicos y 
económicos.   
Los datos obtenidos sugieren que efectivamente, los pacientes con un resultado positivo 
tendrán una evolución clínicamente distinta a aquellos con un resultado negativo, presentando un 
mayor riesgo de recaída, un mayor número medio de días de hospitalización y un mayor coste en su 
tratamiento. Es importante remarcar que, aunque se necesitan estudios prospectivos para confirmar 
este hecho, los datos del Estudio 2 sugieren que el etilglucurónido es en efecto una herramienta 
potencialmente útil en la mejora de la prevención de recaídas, pues permitiría a los profesionales 
conocer con mucha antelación el estado clínico de los pacientes. Los datos apuntan a que un EtG 
positivo debería alertar rápidamente a los profesionales responsables en cuanto a la necesidad de 
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abordar el consumo y el riesgo de recaída. Por el contrario, un resultado negativo sugeriría que en 
los siguientes meses el paciente es capaz de mantener la abstinencia. Por tanto, el EtG presenta un 
elevado poder predictivo tanto positivo como negativo, un hecho relevante de cara a la práctica 
clínica habitual. Estudios previos apuntaban conclusiones similares a las obtenidas en el Estudio 2 
(62,98).   
En cuanto a los costes de tratamiento, cabe destacar que el mayor gasto de los pacientes 
EtG positivo vino dado por un mayor número de hospitalizaciones y un mayor número de visitas con 
los profesionales pertinentes. Estos datos están en línea con múltiples evidencias previas que 
sugieren que los pacientes no abstinentes incurren en mayores gastos sanitarios (103–105). Este 
hecho sugiere que la implementación del EtG podría tener también importantes implicaciones 
económicas.  
Finalmente, aunque los resultado no fueron significativos para EtG en cuanto al riesgo de 
abandonar tratamiento, estudios previos señalan que, en efecto, el consumo activo de drogas es un 
factor de riesgo para abandonar tratamiento (106,108,109), por lo que, pese a la falta de significación 
estadística, cabe la posibilidad de que el EtG también posea cierto poder predictivo en cuanto a la 
retención de los pacientes en el tratamiento de su dependencia, hecho ya señalado por estudios 
previos (62).  
Aunque existen muchas otras variables de poder predictivo demostrando en el campo del 
alcohol (106-112), ninguna de ellas en nuestro estudio obtuvo resultados similares a los del EtG, ni si 
quiera el juicio clínico. Esto no implica que el EtG deba sustituir a muchas de estas variables, pero 
parece evidente que de tener en cuenta su resultado en la valoración global de los pacientes, las 
conclusiones a las que se puedan llegar serán mucho más cercanas a la realidad y por tanto de una 
mayor validez.  
 
La perspectiva de los pacientes  
 
La aparición de nuevos biomarcadores con elevada sensibilidad y especificidad ha hecho 
patente el bajo rendimiento del cribado rutinario de alcohol con marcadores tradicionales. Muestra de 
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ello son los resultados del Estudio 1, así como todos los estudios previos llevados a cabo con 
etilglucurónido. Esto sugiere diversos interrogantes, en relación a qué función cumple realmente el 
cribado de orina en los pacientes dependientes del alcohol. ¿Se trata de una función de control, un 
manejo de contingencias, una prevención de recaídas? ¿O existen otras funciones como ofrecer 
soporte continuado y el fomento de hábitos regulares? ¿O son ambas cosas? Esto es en parte lo que 
se trató de desvelar en el Estudio 3.  
En su global, los resultados de dicho estudio sugieren que los pacientes valoran muy 
positivamente el cribado rutinario de alcohol como parte de su tratamiento. De las respuestas de los 
pacientes se desprende que la prevención de recaídas es una función primordial para la mayoría. No 
obstante, una parte importante de los mismos también refiere que tener un contacto más cercano con 
los profesionales y sentirse más atendido son también funciones relevantes, sugiriendo que el factor 
humano juega un papel importante en la dinámica del cribado regular de alcohol en orina. Este hecho 
no es sorprendente, pues estudios previos ya demuestran la importancia de la relación terapéutica en 
el campo del alcoholismo (117,118). También estudios previos apuntan a que los pacientes prefieren 
tratamientos que implican contacto humano frente a tratamientos computarizados (119), y que es 
primordial para los pacientes afectos de un trastorno adictivo percibir que sus profesionales se 
preocupan por ellos (120). Cabe destacar también el elevado número de participantes que 
respondieron como función el demostrar a su familia y sus profesionales que no beben, apuntando 
también a la importancia de la conveniencia social y el manejo de impresiones.  
Respecto a los conocimientos técnicos de los pacientes, se hizo patente que el 
etilglucurónido es un gran desconocido para ellos. En especial en lo que a su ventana de detección 
concierne, hecho que podría ayudar a explicar las grandes discrepancias que se encuentran cuando 
se compara con el etanol (61,63,65,76,121). Los datos en su conjunto apuntan a la posibilidad de que 
muchos pacientes, teniendo conocimientos suficientes sobre la farmacocinética del etanol, podrían 
tratar de autorregular sus consumos para evitar cribados positivos. La pregunta que aparece 
rápidamente es si podrán, una vez implementado el EtG y conocidas sus características, readaptar 
su consumo para seguir evitando cribados positivos o si la prolongada ventana de detección del EtG 






En su global, esta tesis enriquece la evidencia disponible en relación al cribado rutinario de 
alcohol en orina en pacientes dependientes al alcohol. Los datos aportados confirman que el 
etilglucurónido presenta en condiciones rutinarias de práctica clínica habitual, una elevada 
sensibilidad para la detección del consumo reciente, convirtiéndose así en una herramienta idónea 
para la monitorización de la abstinencia.  
Además, sus resultados tienen un elevado poder predictivo en relación al riesgo de recaída y 
el riesgo de hospitalización en los siguientes 12 meses, así como también en cuestiones de costes 
de tratamiento. Por otro lado, los pacientes tienen un bajo conocimiento de las características 
farmacocinéticas del etilglucurónido, siendo especialmente importante el desconocimiento de su 
amplia ventana de detección. No obstante, los pacientes valoran muy favorablemente el cribado 
rutinario de alcohol en orina como parte de su tratamiento, destacando como funciones importantes 
la prevención de recaídas, una relación terapéutica más cercana y el manejo de impresiones en 








































List of abbreviations  
 
 
AUC area under the curve 
AUD alcohol use disorder 
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MCV mean corpuscular volume 
PEth phosphatidylethanol 
ROC receiving operator curve 





















































1.  Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. 
Global burden of disease and injury and economic cost attributable to alcohol use and 
alcohol-use disorders. Lancet . 2009;373(9682):2223–33.  
2.  WHO | Global status report on alcohol and health 2014. WHO. World Health 
Organization; 2016. 
3.  Dugum M, McCullough A. Diagnosis and Management of Alcoholic Liver Disease. J 
Clin Transl Hepatol . 2015;3(2):109–16.  
4.  Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual Causes of Death in the 
United States, 2000. JAMA . 2004;10;291(10):1238.  
5.  Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The 
size and burden of mental disorders and other disorders of the brain in Europe 2010. 
Eur Neuropsychopharmacol . 2011;21(9):655–79.  
6.  Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. 
Prevalence of mental disorders in Europe: results from the European Study of the 
Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl . 
2004;(420):21–7.  
7.  Rehm J, Anderson P, Barry J, Dimitrov P, Elekes Z, Feijão F, et al. Prevalence of and 
potential influencing factors for alcohol dependence in Europe. Eur Addict Res . 
2015;21(1):6–18.  
8.  Barrio P, Miquel L, Moreno-España J, Martínez A, Ortega L, Teixidor L, et al. Alcohol 
in Primary Care. Differential characteristics between alcohol-dependent patients who 
are receiving or not receiving treatment. Adicciones . 2016;28(2):116–22.  
9.  Barrio P, Reynolds J, García-Altés A, Gual A, Anderson P. Social costs of illegal 
drugs, alcohol and tobacco in the European Union: a systematic review. Drug Alcohol 
Rev. 2017. 
10.  Mohapatra S, Patra J, Popova S, Duhig A, Rehm J. Social cost of heavy drinking and 
alcohol dependence in high-income countries. Int J Public Health . 2010;55(3):149–
57.  
11.  Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American 
Psychiatric Association; 2013.  
12.  Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the 
United States? J Stud Alcohol . 200;62(2):211–20.  
13.  Merkx MJM, Schippers GM, Koeter MWJ, Vuijk PJ, Oudejans SCC, Stam RK, et al. 
Guidelines for allocating outpatient alcohol abusers to levels of care: Predictive 
validity. Addict Behav . 2011;36(6):570–5.  
14.  Vaillant GE. A 60-year follow-up of alcoholic men. Addiction . 2003;98(8):1043–51.  
15.  Agrawal A, Lynskey MT. Are there genetic influences on addiction: evidence from 
family, adoption and twin studies. Addiction . 2008;103(7):1069–81.  
16.  Palmer RHC, McGeary JE, Heath AC, Keller MC, Brick LA, Knopik VS. Shared 
additive genetic influences on DSM-IV criteria for alcohol dependence in subjects of 
European ancestry. Addiction . 2015;110(12):1922-31 
17.  Prescott CA, Kendler KS. Genetic and Environmental Contributions to Alcohol Abuse 
95 
 
and Dependence in a Population-Based Sample of Male Twins. Am J Psychiatry . 
1999;156(1):34–40.  
18.  Saitz R. Medical and surgical complications of addiction. In: Ries RK, Fiellin DA, Miller 
S, Saitz R, editors. Principles of Addiction Medicine. 5th ed. American Society of 
Addiction Medicine; 2014. p. 1062.  
19.  Edelman EJ, Fiellin DA. In the Clinic. Alcohol Use. Ann Intern Med . 
2016;164(1):ITC1-16.  
20.  Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver 
cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. 
BMC Med . 2014;12(1):145.  
21.  Anderson P, Gual A, Colom J. Alcohol and Primary Health Care: Clinical Guidelines 
on Identification and Brief Interventions. Catalonia D of H of the G of, editor. 
Barcelona; 2005 p.  
22.  Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling 
interventions in primary care to reduce risky/harmful alcohol use by adults: a summary 
of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med . 
2004;140(7):557–68.  
23.  European Medicines Agency. Guideline on the development of medicinal products for 
the treatment of alcohol dependence. 2010;  
24.  Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, et al. 
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for 
Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. 
World J Biol Psychiatry . 2008;9(1):6–23.  
25.  Smedslund G, Berg RC, Hammerstrøm KT, Steiro A, Leiknes KA, Dahl HM, et al. 
Motivational interviewing for substance abuse. Cochrane database Syst Rev . 
2011;(5):CD008063.  
26.  Vasilaki EI, Hosier SG, Cox WM. The efficacy of motivational interviewing as a brief 
intervention for excessive drinking: a meta-analytic review. Alcohol Alcohol 
.;41(3):328–35.  
27.  Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug 
users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs . 
2009;70(4):516–27.  
28.  Manuel JK, Austin JL, Miller WR, McCrady BS, Tonigan JS, Meyers RJ, et al. 
Community Reinforcement and Family Training: a pilot comparison of group and self-
directed delivery. J Subst Abus Treat. 2012;43(1):129–36.  
29.  Benishek LA, Dugosh KL, Kirby KC, Matejkowski J, Clements NT, Seymour BL, et al. 
Prize-based contingency management for the treatment of substance abusers: a 
meta-analysis. Addiction . 2014;109(9):1426–36.  
30.  Petry NM, Martin B, Cooney JL, Kranzler HR. Give them prizes, and they will come: 
contingency management for treatment of alcohol dependence. J Consult Clin 
Psychol . 2000;68(2):250–7.  
31.  O’Farrell TJ, Clements K. Review of outcome research on marital and family therapy 
in treatment for alcoholism. J Marital Fam Ther . 2012;38(1):122–44.  
32.  United Kingdom Alcohol Treatment Trial (UKATT): hypotheses, design and methods. 
Alcohol Alcohol. 2001;36(1):11–21.  
33.  Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. 
96 
 
Combined pharmacotherapies and behavioral interventions for alcohol dependence: 
the COMBINE study: a randomized controlled trial. Jama. 2006;295(17):2003–17.  
34.  Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. 
Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings. JAMA 
. 2014;311(18):1889.  
35.  Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate 
for alcohol dependence. In: Rösner S, editor. Cochrane Database of Systematic 
Reviews . Chichester, UK: John Wiley & Sons, Ltd; 2010 p. CD004332.  
36.  Skinner MD, Lahmek P, Pham H, Aubin H-J. Disulfiram Efficacy in the Treatment of 
Alcohol Dependence: A Meta-Analysis. Laks J, editor. PLoS One . 2014 ;9(2):e87366.  
37.  Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of 
alcohol dependence: a review of the evidence. JAMA . 1999;281(14):1318–25.  
38.  McLellan AT, Weisner C. Achieving the Public Health and Safety Potential of 
Substance Abuse Treatments. In: Drug Policy and Human Nature . Boston, MA: 
Springer US; 1996 . p. 127–54.  
39.  Rehm J, Marmet S, Anderson P, Gual A, Kraus L, Nutt DJ, et al. Defining substance 
use disorders: do we really need more than heavy use? Alcohol Alcohol 
.2014;48(6):633–40.  
40.  Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF. Reduction in heavy drinking as 
a treatment outcome in alcohol dependence. JSubstAbuse Treat . 2007;33(1):71–80.  
41.  Luquiens A, Reynaud M, Aubin HJ. Is controlled drinking an acceptable goal in the 
treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol 
Alcohol . 2011;46(5):586–91.  
42.  Heilig M, Goldman D, Berrettini W, O’Brien CP. Pharmacogenetic approaches to the 
treatment of alcohol addiction. NatRevNeurosci . 2011;12(11):670–84.  
43.  Owen P, Marlatt GA. Should abstinence be the goal for alcohol treatment? Affirmative 
viewpoint. Am J Addict . 2001;10(4):289-91-5.  
44.  Cox WM, Rosenberg H, Hodgins CHA, Macartney JI, Maurer KA. United Kingdom and 
United States healthcare providers’ recommendations of abstinence versus controlled 
drinking. Alcohol Alcohol .;39(2):130–4.  
45.  Vaillant GE. A long-term follow-up of male alcohol abuse. Arch Gen Psychiatry . 
1996;53(3):243–9.  
46.  Maisto SA, Clifford PR, Longabaugh R, Beattie M. The relationship between 
abstinence for one year following pretreatment assessment and alcohol use and other 
functioning at two years in individuals presenting for alcohol treatment. J Stud Alcohol 
.2002;63(4):397–403.  
47.  Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the 
science and challenges for research. Addiction . Blackwell Publishing Ltd.; 
2003;98(s2):1–12.  
48.  Zemore SE. The effect of social desirability on reported motivation, substance use 
severity, and treatment attendance. J Subst Abuse Treat . 2012;42(4):400–12.  
49.  The Role of Biomarkers in the Treatment of Alcohol Use Disorders, 2012 





50.  Conigrave KM, Saunders JB, Whitfield JB. Diagnostic tests for alcohol consumption. 
Alcohol Alcohol . 1995;30(1):13–26.  
51.  Mihas AA, Tavassoli M. Laboratory markers of ethanol intake and abuse: a critical 
appraisal. Am J Med Sci . 1992;303(6):415–28.  
52.  Hock B, Schwarz M, Domke I, Grunert V, Wuertemberger M, Schiemann U, et al. 
Validity of carbohydrate-deficient transferrin (%CDT), γ-glutamyltransferase (γ-GT) 
and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol 
abuse: a study in patients with alcohol dependence and liver disorders of non-
alcoholic and. Addiction. 2005;100(10):1477–86.  
53.  American Society of Addiction Medicine.Public Policy Statement On Drug Testing as a 
Component of Addiction Treatment and Monitoring Programs and in other Clinical 
Settings. 2010; Available at: http://www.asam.org/docs/default-source/public-policy-
statements/1drug-testing---clinical-10-10.pdf 
54.  Helander A, Eriksson CJP, WHO/ISBRA Study on State and Trait Markers ofAlcohol 
Use and Dependence Investigators. Laboratory tests for acute alcohol consumption: 
results of the WHO/ISBRA Study on State and Trait Markers of Alcohol Use and 
Dependence. Alcohol Clin Exp Res . 2002;26(7):1070–7.  
55.  Halter CC, Dresen S, Auwaerter V, Wurst FM, Weinmann W. Kinetics in serum and 
urinary excretion of ethyl sulfate and ethyl glucuronide after medium dose ethanol 
intake. Int J Legal Med . 2008;122(2):123–8.  
56.  Gurvich EM, Kenna GA, Leggio L. Use of novel technology-based techniques to 
improve alcohol-related outcomes in clinical trials. Alcohol Alcohol .2015;48(6):712–9.  
57.  Helander A, Péter O, Zheng Y. Monitoring of the alcohol biomarkers PEth, CDT and 
EtG/EtS in an outpatient treatment setting. Alcohol Alcohol .2015;47(5):552–7.  
58.  Schröck A, Thierauf A, Wurst FM, Thon N, Weinmann W. Progress in monitoring 
alcohol consumption and alcohol abuse by phosphatidylethanol. Bioanalysis . 
2014;6(17):2285–94.  
59.  Wurst FM, Dresen S, Allen JP, Wiesbeck G, Graf M, Weinmann W. Ethyl sulphate: a 
direct ethanol metabolite reflecting recent alcohol consumption. Addiction . 
2006;101(2):204–11.  
60.  Lostia AM, Vicente JL, Cowan DA. Measurement of ethyl glucuronide, ethyl sulphate 
and their ratio in the urine and serum of healthy volunteers after two doses of alcohol. 
Alcohol Alcohol . ;48(1):74–82.  
61.  Jatlow PI, Agro A, Wu R, Nadim H, Toll BA, Ralevski E, et al. Ethyl glucuronide and 
ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose 
ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res . 
2014;38(7):2056–65.  
62.  Helander A, Böttcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl 
glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol 
Alcohol .2009;44(1):55–61.  
63.  Wojcik MH, Hawthorne JS. Sensitivity of commercial ethyl glucuronide (ETG) testing 
in screening for alcohol abstinence. Alcohol Alcohol .2007;42(4):317–20.  
64.  Leickly E, McDonell MG, Vilardaga R, Angelo FA, Lowe JM, McPherson S, et al. High 
levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and 
laboratory-based mass spectrometry. Am J Drug Alcohol Abuse . 2015;41(3):246–50.  
65.  Dahl H, Hammarberg A, Franck J, Helander A. Urinary ethyl glucuronide and ethyl 
98 
 
sulfate testing for recent drinking in alcohol-dependent outpatients treated with 
acamprosate or placebo. Alcohol Alcohol . 2011;46(5):553–7.  
66.  Junghanns K, Graf I, Pflüger J, Wetterling G, Ziems C, Ehrenthal D, et al. Urinary 
ethyl glucuronide (EtG) and ethyl sulphate (EtS) assessment: valuable tools to 
improve verification of abstention in alcohol-dependent patients during in-patient 
treatment and at follow-ups. Addiction . 2009;104(6):921–6.  
67.  Wurst FM, Wiesbeck GA, Metzger JW, Weinmann W. On sensitivity, specificity, and 
the influence of various parameters on ethyl glucuronide levels in urine--results from 
the WHO/ISBRA study. Alcohol Clin Exp Res . 2004;28(8):1220–8.  
68.  Pearson M, Coomber R. The challenge of external validity in policy-relevant 
systematic reviews: a case study from the field of substance misuse. Addiction . 
2010;105(1):136–45.  
69.  Dekkers OM, von Elm E, Algra A, Romijn JA, Vandenbroucke JP. How to assess the 
external validity of therapeutic trials: a conceptual approach. Int J Epidemiol . 
2010;39(1):89–94.  
70.  Rothwell PM. External validity of randomised controlled trials: “to whom do the results 
of this trial apply?”. Lancet .2005;365(9453):82–93.  
71.  Hoertel N, de Maricourt P, Katz J, Doukhan R, Lavaud P, Peyre H, et al. Are 
participants in pharmacological and psychotherapy treatment trials for social anxiety 
disorder representative of patients in real-life settings? J Clin Psychopharmacol . 
2014;34(6):697–703. 
72.  Uijen AA, Bakx JC, Mokkink HGA, van Weel C. Hypertension patients participating in 
trials differ in many aspects from patients treated in general practices. J Clin 
Epidemiol . 2007;60(4):330–5. 
73.  Persaud N, Mamdani MM. External validity: the neglected dimension in evidence 
ranking. J Eval Clin Pract . 2006;12(4):450–3.  
74.  Wetterling T, Dibbelt L, Wetterling G, Göder R, Wurst F, Margraf M, et al. Ethyl 
glucuronide (EtG): better than breathalyser or self-reports to detect covert short-term 
relapses into drinking. Alcohol Alcohol .2014;49(1):51–4.  
75.  Lahmek P, Michel L, Diviné C, Meunier N, Pham B, Cassereau C, et al. Ethyl 
glucuronide for detecting alcohol lapses in patients with an alcohol use disorder. J 
Addict Med . 2012;6(1):35–8.  
76.  Wurst FM, Vogel R, Jachau K, Varga A, Alling C, Alt A, et al. Ethyl glucuronide 
discloses recent covert alcohol use not detected by standard testing in forensic 
psychiatric inpatients. Alcohol Clin Exp Res . 2003;27(3):471–6.  
77.  Wurst FM, Haber PS, Wiesbeck G, Watson B, Wallace C, Whitfield JB, et al. 
Assessment of alcohol consumption among hepatitis C-positive people receiving 
opioid maintenance treatment using direct ethanol metabolites and self-report: a pilot 
study. Addict Biol . 2008;13(3–4):416–22.  
78.  Dupouy J, Mémier V, Catala H, Lavit M, Oustric S, Lapeyre-Mestre M. Does urine 
drug abuse screening help for managing patients? A systematic review. Drug Alcohol 
Depend . 2014;136:11–20.  
79.  Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st 
Century. 2012. Available at: 
https://www.ncbi.nlm.nih.gov/books/NBK222274/pdf/Bookshelf_NBK222274.pdf 
80.  Bradley KA, Kivlahan DR. Bringing patient-centered care to patients with alcohol use 
99 
 
disorders. JAMA . 2014;311(18):1861–2.  
81.  Barrio P, Gual A. Patient-centered care interventions for the management of alcohol 
use disorders: a systematic review of randomized controlled trials. Patient Prefer 
Adherence . 2016; 10:1823–45.  
82.  Reisfield GM, Bertholf R, Barkin RL, Webb F, Wilson G. Urine drug test interpretation: 
what do physicians know? J Opioid Manag .2007;3(2):80–6 
83.  Pergolizzi J, Pappagallo M, Stauffer J, Gharibo C, Fortner N, De Jesus MN, et al. The 
role of urine drug testing for patients on opioid therapy. Pain Pract .2010;10(6):497–
507.  
84.  Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current 
recommendations and best practices. Pain Physician . 2012;15(3 Suppl):ES119-33.  
85.  Starrels JL, Fox AD, Kunins H V, Cunningham CO. They don’t know what they don’t 
know: internal medicine residents’ knowledge and confidence in urine drug test 
interpretation for patients with chronic pain. J Gen Intern Med . 2012;27(11):1521–7.  
86.  Kirsh KL, Baxter LE, Rzetelny A, Mazuk M, Passik SD. A Survey of ASAM Members’ 
Knowledge, Attitudes, and Practices in Urine Drug Testing. J Addict Med 
.2015;9(5):399–404.  
87.  Kamila IA, Smith JN, Williams RT. Studies in detoxication. L. The isolation of methyl 
and ethyl glucuronides from the urine of rabbits receiving methanol and ethanol. 
Biochem J . 1953;54(3):390–2.  
88.  Schmitt G, Droenner P, Skopp G, Aderjan R. Ethyl glucuronide concentration in serum 
of human volunteers, teetotalers, and suspected drinking drivers. J Forensic Sci . 
1997;42(6):1099–102.  
89.  Schmitt G, Aderjan R, Keller T, Wu M. Ethyl glucuronide: an unusual ethanol 
metabolite in humans. Synthesis, analytical data, and determination in serum and 
urine. J Anal Toxicol .1995;19(2):91–4.  
90.  Wurst FM, Kempter C, Seidl S, Alt A. Ethyl glucuronide--a marker of alcohol 
consumption and a relapse marker with clinical and forensic implications. Alcohol 
Alcohol . 2000;34(1):71–7.  
91.  McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: 
new concepts are needed to study research participation effects. J Clin Epidemiol . 
2014;67(3):267–77. 
92.  Mutschler J, Grosshans M, Koopmann A, Mann K, Kiefer F, Hermann D. Urinary 
ethylglucuronide assessment in patients treated with disulfiram: a tool to improve 
verification of abstention and safety. Clin Neuropharmacol .2010;33(6):285–7.  
93.  Skipper GE, Weinmann W, Thierauf A, Schaefer P, Wiesbeck G, Allen JP, et al. Ethyl 
glucuronide: a biomarker to identify alcohol use by health professionals recovering 
from substance use disorders. Alcohol Alcohol .2004;39(5):445–9.  
94.  Sommers MS, Dyehouse JM, Howe SR, Lemmink J, Volz T, Manharth M. Validity of 
self-reported alcohol consumption in nondependent drinkers with unintentional 
injuries. Alcohol Clin Exp Res . 2000;24(9):1406–13.  
95.  Livingston M, Callinan S. Underreporting in alcohol surveys: whose drinking is 
underestimated? J Stud Alcohol Drugs . 2015;76(1):158–64.  
96.  de Beaurepaire R, Lukasiewicz M, Beauverie P, Castéra S, Dagorne O, Espaze R, et 
al. Comparison of self-reports and biological measures for alcohol, tobacco, and illicit 
drugs consumption in psychiatric inpatients. Eur Psychiatry . 2007;22(8):540–8.  
100 
 
97.  Searles JS, Perrine MW, Mundt JC, Helzer JE. Self-report of drinking using touch-
tone telephone: extending the limits of reliable daily contact. J Stud Alcohol . 
1995;56(4):375–82.  
98.  Reidy LJ, Junquera P, Van Dijck K, Steele BW, Nemeroff CB. Underestimation of 
substance abuse in psychiatric patients by conventional hospital screening. J 
Psychiatr Res . 2014;59:206–12.  
99.  Witkiewitz K. Lapses following alcohol treatment: modeling the falls from the wagon. J 
Stud Alcohol Drugs . 2008;69(4):594–604.  
100.  Witkiewitz K, Masyn KE. Drinking trajectories following an initial lapse. Psychol Addict 
Behav . 2008;22(2):157–67.  
101.  Maisto SA, Witkiewitz K, Moskal D, Wilson AD. Is the Construct of Relapse Heuristic, 
and Does It Advance Alcohol Use Disorder Clinical Practice? J Stud Alcohol Drugs . 
2016;77(6):849–58.  
102.  Dahl H, Voltaire Carlsson A, Hillgren K, Helander A. Urinary ethyl glucuronide and 
ethyl sulfate testing for detection of recent drinking in an outpatient treatment program 
for alcohol and drug dependence. Alcohol Alcohol .2011;46(3):278–82.  
103.  Miquel L, Gual A, Vela E, Lligoña A, Bustins M, Colom J, et al. Alcohol Consumption 
and Inpatient Health Service Utilization in a Cohort of Patients With Alcohol 
Dependence After 20 Years of Follow-up. Alcohol Alcohol. 2016; 9;52(2):227-233. 
104.  Aldridge AP, Zarkin GA, Dowd WN, Bray JW. The Relationship Between End-of-
Treatment Alcohol Use and Subsequent Healthcare Costs: Do Heavy Drinking Days 
Predict Higher Healthcare Costs? Alcohol Clin Exp Res . 2016;40(5):1122–8.  
105.  Witkiewitz K, Horn BP. Reductions in Healthcare Costs Following Alcohol Treatment: 
Moving Toward Low-Risk Drinking End Points in Alcohol Clinical Trials. Alcohol Clin 
Exp Res . 2016;40(7):1415–7.  
106.  Haug S, Schaub MP. Treatment outcome, treatment retention, and their predictors 
among clients of five outpatient alcohol treatment centres in Switzerland. BMC Public 
Health . 2016;16(1):581.  
107.  Korte J, Wakim P, Rosa C, Perl H. Addiction treatment trials: how gender, 
race/ethnicity, and age relate to ongoing participation and retention in clinical trials. 
Subst Abuse Rehabil . 2011; 22;2:205-18.  
108.  Campbell MD, Kolodner G, Spencer RA, DuPont RL. Drug test results as a predictor 
of retention among patients using buprenorphine in a comprehensive outpatient 
treatment program. J Addict Dis . 2016;35(4):315–24.  
109.  White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. 
Patterns of Abstinence or Continued Drug Use Among Methadone Maintenance 
Patients and Their Relation to Treatment Retention. J Psychoactive Drugs . 
2014;46(2):114–22.  
110.  Langenbucher J, Sulesund D, Chung T, Morgenstern J. Illness severity and self-
efficacy as course predictors of DSM-IV alcohol dependence in a multisite clinical 
sample. Addict Behav .1996;21(5):543–53.  
111.  Bttlender M, Soyka M. Impact of craving on alcohol relapse during, and 12 months 
following, outpatient treatment. Alcohol Alcohol . 2004;39(4):357–61.  
112.  Fazzino TL, Rose GL, Burt KB, Helzer JE. Comparison of categorical alcohol 
dependence versus a dimensional measure for predicting weekly alcohol use in heavy 
drinkers. Drug Alcohol Depend . 2014;136:121–6.  
101 
 
113.  Cannon DS, Keefe CK, Clark LA. Persistence predicts latency to relapse following 
inpatient treatment for alcohol dependence. Addict Behav .1997;22(4):535–43.  
114.  Chang G, Martin KB, Tang M, Fleming JA. Inpatient hospitalization for substance use 
disorders one year after residential rehabilitation: predictors among US veterans. Am 
J Drug Alcohol Abuse . 2016 ;42(1):56–62.  
115.  Hong H-S, Park J-E, Park W-J. Predictors of Hospitalization for Alcohol Use Disorder 
in Korean Men. J Korean Acad Nurs . 2014 ;44(5):552.  
116.  Lawder R, Grant I, Storey C, Walsh D, Whyte B, Hanlon P. Epidemiology of 
hospitalization due to alcohol-related harm: evidence from a Scottish cohort study. 
Public Health . 2011;125(8):533–9.  
117.  Ritter A, Bowden S, Murray T, Ross P, Greeley J, Pead J. The influence of the 
therapeutic relationship in treatment for alcohol dependency. Drug Alcohol Rev . 
2002;21(3):261–8.  
118.  Ilgen MA, McKellar J, Moos R, Finney JW. Therapeutic alliance and the relationship 
between motivation and treatment outcomes in patients with alcohol use disorder. J 
Subst Abuse Treat . 2006;31(2):157–62.  
119.  Tucker JA, Foushee HR, Simpson CA. Increasing the appeal and utilization of 
services for alcohol and drug problems: what consumers and their social networks 
prefer. Int J Drug Policy . 2009;20(1):76–84.  
120.  Press KR, Zornberg GZ, Geller G, Carrese J, Fingerhood MI. What patients with 
addiction disorders need from their primary care physicians: A qualitative study. Subst 
Abus .2016;37(2):349–55.  
121.  Böttcher M, Beck O, Helander A. Evaluation of a new immunoassay for urinary ethyl 
glucuronide testing. Alcohol Alcohol .2008;43(1):46–8.  
122.  Lowe JM, McDonell MG, Leickly E, Angelo FA, Vilardaga R, McPherson S, et al. 
Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in 
addiction treatment patients. Alcohol Clin Exp Res . 2015;39(5):905–10.  
123.  Ondersma SJ, Beatty JR, Rosano TG, Strickler RC, Graham AE, Sokol RJ. 
Commercial Ethyl Glucuronide (EtG) and Ethyl Sulfate (EtS) Testing is Not Vulnerable 
to Incidental Alcohol Exposure in Pregnant Women. Subst Use Misuse. 
2016;51(1):126–30.  
124.  Reisfield GM, Goldberger BA, Pesce AJ, Crews BO, Wilson GR, Teitelbaum SA, et al. 
Ethyl glucuronide, ethyl sulfate, and ethanol in urine after intensive exposure to high 
ethanol content mouthwash. J Anal Toxicol . 2011;35(5):264–8.  
125.  Høiseth G, Yttredal B, Karinen R, Gjerde H, Christophersen A. Levels of ethyl 
glucuronide and ethyl sulfate in oral fluid, blood, and urine after use of mouthwash 
and ingestion of nonalcoholic wine. J Anal Toxicol . 2010;34(2):84–8.  
126.  Stewart SH, Koch DG, Burgess DM, Willner IR, Reuben A. Sensitivity and specificity 
of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. Alcohol Clin Exp 
Res . 2013;37(1):150–5. 
 127.  Ferreira-González I, Alonso-Coello P, Solà I, Pacheco-Huergo V, Domingo-Salvany A, 
Alonso J, et al. Composite Endpoints in Clinical Trials. Rev Española Cardiol (English 
Ed . Elsevier; 2008;61(3):283–90.  
128.  Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and 
interpretation of composite outcomes in clinical trials: systematic review. BMJ . 
2010;341(aug18 3):c3920–c3920.  
102 
 
129.  Fein G. Psychiatric Comorbidity in Alcohol Dependence. Neuropsychol Rev . 
2015;25(4):456–75.  
130.  Flensborg-Madsen T, Mortensen EL, Knop J, Becker U, Sher L, Grønbæk M. 
Comorbidity and temporal ordering of alcohol use disorders and other psychiatric 
disorders: results from a Danish register-based study. Compr Psychiatry . 
2009;50(4):307–14.  
131.  Van De Mortel TF, Van De Mortel Rn TF. Faking it: social desirability response bias in 
self- report research Faking it: social desirability response bias in self‑ report 
research. Aust J Adv Nurs Aust J Adv Nurs Aust J Adv Nurs . 2008;25(4):40–8.  
132.  Davis CG, Thake J, Vilhena N. Social desirability biases in self-reported alcohol 
consumption and harms. Addict Behav . 2010;35(4):302–11.  
133.  Zemore SE. The effect of social desirability on reported motivation, substance use 
severity, and treatment attendance. J Subst Abuse Treat . 2012;42(4):400–12.  
134.  Little JM. Humanistic medicine or values-based medicine. what’s in a name? Med J 
Aust . 2002;177(6):319–21.  
135.  Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to 
evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med . 
2006;144(11):850–5.  
136.  Lu B, Gatsonis C. Efficiency of study designs in diagnostic randomized clinical trials. 
Stat Med . 2013;32(9):1451–66.  
137.  Rodger M, Ramsay T, Fergusson D. Diagnostic randomized controlled trials: the final 
frontier. Trials . 2012;13:137.  
138.  Kummer N, Ingels A-S, Wille SMR, Hanak C, Verbanck P, Lambert WEE, et al. 
Quantification of phosphatidylethanol 16:0/18:1, 18:1/18:1, and 16:0/16:0 in venous 
blood and venous and capillary dried blood spots from patients in alcohol withdrawal 
and control volunteers. Anal Bioanal Chem . 2016;408(3):825–38.  
139.  Bakhireva LN, Shrestha S, Gutierrez HL, Berry M, Schmitt C, Sarangarm D. Stability 
of Phosphatidylethanol in Dry Blood Spot Cards. Alcohol Alcohol . 2016;51(3):275–80.  
140.  Faller A, Richter B, Kluge M, Koenig P, Seitz HK, Thierauf A, et al. LC-MS/MS 
analysis of phosphatidylethanol in dried blood spots versus conventional blood 
specimens. Anal Bioanal Chem . 2011;401(4):1163–6.  
141.  Nissinen AE, Mäkelä SM, Vuoristo JT, Liisanantti MK, Hannuksela ML, Hörkkö S, et 
al. Immunological Detection of in Vitro Formed Phosphatidylethanol—An Alcohol 
Biomarker—With Monoclonal Antibodies. Alcohol Clin Exp Res . 2008 J;32(6):921–8.  
142.  Liangpunsakul S, Lai X, Ross RA, Yu Z, Modlik E, Westerhold C, et al. Novel serum 
biomarkers for detection of excessive alcohol use. Alcohol Clin Exp Res . NIH Public 
Access; 2015;39(3):556–65.  
143.  Torrente MP, Freeman WM, Vrana KE. Protein biomarkers of alcohol abuse. Expert 
Rev Proteomics . 2012;9(4):425–36.  
144.  Jastrzębska I, Zwolak A, Szczyrek M, Wawryniuk A, Skrzydło-Radomańska B, Daniluk 
J. Biomarkers of alcohol misuse: recent advances and future prospects. Prz 

















































Cuando uno termina algo como un doctorado, es imposible no pensar en la cantidad de 
gente que te ha ayudado, de manera directa o indirecta, a conseguir dicha meta. Y te invade una 
cierta ola de gratitud.  
En primer lugar no puedo dejar de mencionar a mis padres. Su dedicación, amor y 
generosidad han sido fundamentales a lo largo de mi vida. Temo no ser capaz de agradecerles cómo 
se merecen todo lo que han hecho (y hacen) por mí.  
Tampoco puedo dejar de mencionar a mis hermanos. Mi hermano Fermín, un ejemplo de 
lucha, superación y generosidad. Mi hermana María, que me enseñó a leer y a escribir, y también el 
teorema de Pitágoras y a atarme los zapatos, y que tanto cariño me ha dado en lo que llevo en esta 
vida. Y mi hermano Diego, con el que comparto muchas más cosas de lo que seguramente ambos 
pensamos, y de quién mi identidad y cómo se ha forjado no se pueden desligar.  
Y mis amigos, aquellos que me escuchan sin juzgarme y me hacen entender qué bonito es 
poder experimentar la amistad en esta vida.  
Dentro de este, nuestro Hospital, hay también mucha gente a la que estoy sinceramente 
agradecido. Començant pels meus directors de tesi, l’Eduard Vieta i el Toni Gual. A l’Eduard, a part 
de tota l’ajuda proporcionada per a tirar endavant aquesta tesi li estic agraït per donar-me l’oportunitat 
de treballar a prop d’una persona del seu nivell. Al Toni Gual de la mateixa manera li haig d’agraïr 
l’oportunitat d’aprendre al seu costat. No només és una persona amb una ment brillant, sinó que té 
una qualitat humana també brillant. Crec que mai vaig arribar a dir-li gràcies per com em va tractar 
quan era R4 i vaig atravessar una petita crisi existencial amb la Psiquiatria. Em va ensenyar què 
significa ser motivacional de veritat. Gràcies.  
La meva gratitud va també cap a tota la Unitat de Conductes Addictives de l’Hospital Clínic, 
per fer-me sentir part de la mateixa i per haver-me acollit desde que era resident d’una manera tan 
amable, sincera i real. I la Lídia, la nostra infermera, que s’enfada amb mi quan anomeno en públic 
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com d’indispensable és per a nosaltres i de quina manera tan excel·lent fa la seva feina…espero que 
no s’enfadi gaire amb mi per aquestes línies, però de veritat que sense ella i la seva feina i la seva 
dediació als pacients, aquesta tesi hagués estat impossible. I la Lluisa, que a la seva manera es 
preocupa i s’ocupa de mi aquí abaix a l’ambulatori. Gràcies Lluisa. Estic segur que ben aviat tornaràs 
a somriure. I la Mercè, i la Neus, i la Presen, i la Nayara,  i l’Hugo, i la Laia, i l’Anna, I l’Ana, i el 
Miquel, i el Pol…i com no, la Sílvia Mondon, a estones companya, a estones amiga, a estones 
confessora i a estones mestre i mirall d’on intentar aprendre continuament, no només sobre 
addiccions. Em sobren motius per dir-li gràcies, però crec que en un momento com aquest cal 
remarcar com em va fer possible continuar dins la unitat quan no vaig obtenir la beca fi de residencia. 
Amb tota sinceritat, gràcies Sílvia! 
I sense sortir de les parets de l’Hospital, no puc deixar de pensar en les grans persones que 
vaig descobrir mentres feia la residència. A l’Àlex González m’agradiria donar-li les gràcies per donar-
me l’oportunitat de descubrir que es poden fer amics de veritat a qualsevol edat, i per fer-me sentir 
sempre que tinc algú a prop que em cuida i em protegeix si cal. Al Diego Hidalgo també haig d’agraïr-
li no només la seva amistat, sinó també la seva generositat amb mi desde que érem residents de 
primer any. Els qui el coneixen ja ho saben: és una persona gran de ment, cor i esperit.  
I moltíssima altra gent que he anat trobant pel camí i que d’alguna manera o d’altra tenen una 
petita part de l’explicació de qui sóc i què faig avui en dia. Encara que no us esmenti a tots i 
cadascun, voldria donar-vos les gràcies.  
I finalment, no per ser menys importants, sino tot el contrari. Perquè són els dos pilars 
fonamentals de la meva vida. La Maria i el Martí. A tu Maria vull dir-te gràcies per fer-me sentir 
estimat tal i com sóc, per fer-me perdre la por tants cops i per haver-me regalat les millors coses 
d’aquesta vida. I a tu Martí, que avui quan escric aquestes línies encara no t’ho puc explicar, però 
espero poder-te transmetre algun dia tot el que signifiques per a mi. Us estimo amb tot el meu cor.  
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